

PRIVATE AND CONFIDENTIAL

JMI SYRINGES & MEDICAL DEVICES LTD.

72/C Progoti Shoroni, Middle Badda, Dhaka - 1212

=====

**Auditor's Report & Financial Statements
For the year ended June 30, 2025**



G. KIBRIA & CO.
CHARTERED ACCOUNTANTS

Head Office:

**SADHARAN BIMA SADAN (5TH FLOOR)
24-25, DILKUSHA COMMERCIAL AREA,
DHAKA-1000, BANGLADESH**

Branch Office :

**Plot 51, Floor-2, Road 14, Block-G, Niketon
Gulshan-1, Dhaka-1212**

TEL OFF : +88 02-223388071, 223355324, 48812331, 48812332

E-mail : kibria03@hotmail.com

: gkibria@gkibriaandco.com

Web : http://gkibriaandco.com

**JMI SYRINGES & MEDICAL
DEVICES LTD.**

72/C Progoti Shoroni, Middle Badda, Dhaka - 1212

**Auditor's Report & Financial Statements
For the year ended June 30, 2025**



Independent Auditor's Report

To the Shareholders of JMI Syringes & Medical Devices Limited

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of JMI Syringes & Medical Devices Limited ("the Company"), which comprise the statement of financial position as at June 30, 2025 and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including material accounting Policy Information.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as at June 30, 2025 and of its financial performance and its cash flows for the year then ended in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB). The Companies Act 1994, The Securities and Exchange Rules 2020 and other applicable laws and regulations.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code), together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

We draw your attention to Note # 5.01 (ii) to the financial statements, which describes the status of Damage Inventory. Our opinion is not modified in respect of this matter.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. In addition to the matter described in the Opinion section we have determined the matters described below to be the key audit matters to be communicated in our report

| KEY AUDIT MATTER | How our audit addresses the Key Audit Matter |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Property, Plant & Equipment | |
| The Company's PPE balance as at 30 June 2025 was BDT 132.93 Crore (BDT 138.59 Crore as at 30 June 2024). This represents 44% of Total Assets of the Company (47% of the Company as at 30 June 2024). There is estimation performed by management in regards to Asset useful life. Based on the requirement of estimates and the fact that this is a major asset category, this was determined to be a key audit matter. | Our audit procedures included: <ul style="list-style-type: none"> ► Obtain an understanding of Company's internal controls, systems and processes around PPE. ► We performed PPE additions procedures by obtaining supporting documentation, invoices and payments support. ► We performed reasonability of depreciation expenses charged by management to ensure accuracy and occurrence. ► Reviewed management's calculations to ensure it is free from no clerical errors. |
| Detailed notes regarding Property, Plant & Equipment has been included in Note 4.01 in the Financial Statements | |

Ref: GKC/25-26/A/133

Head Office: Sadharan Bima Sadan (5th Floor), 24-25 Dikusha Commercial Area, Dhaka – 1000, Bangladesh

Branch Office: House 51, Road 14, Block G, Niketon, Gulshan-1, Dhaka-1212

Email: gkibria@gkibriaandco.com, kibria03@hotmail.com, **Web:** http://gkibriaandco.com

Tel: +02-223-355-324, +02-4881-2331, +02-4881-2332



Information Other than the Financial Statements and Auditor's Report Thereon

Management is responsible for information other than financial statements and auditor's report. The other information comprises of the Director's Report, Corporate Governance Compliance Report, Business Responsibility & Sustainability Report and Management Discussion and Analysis. We expect to receive this other information after the date of our auditor's report.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated and separate financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed on the other information obtained prior to the date of the auditor's report, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board (IASB), The Companies Act 1994, The Securities and Exchange Rules 2020 and other applicable laws and regulations. and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. The Companies Act, 1994 require the management to ensure effective internal audit, internal control and risk management functions of the company.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company's or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- ▶ Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- ▶ Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.



- ▶ Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- ▶ Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- ▶ Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

In accordance with the Companies Act 1994, The Securities and Exchange Rules 2020 and relevant notifications issues by Bangladesh Securities and Exchange Commission, we also report the following:

- ▶ we have obtained all the information and explanation which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;
- ▶ in our opinion, proper books of account as required by law have been kept by the Company so far as it appeared from our examination of those books; and
- ▶ the statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of account.
- ▶ The expenditures incurred were for the purpose of the Company's business.

Place: Dhaka
Date: 27 October 2025
DVC No. 2510270392AS396923

For and on behalf of
G. Kibria & Co.
Chartered Accountants
Firm's FRC Enlistment No. CAF-001-030


A. K. Gulam Kibria, FCA, (#392)
Engagement Partner

Ref: GKC/25-26/A/133




JMI Syringes & Medical Devices Ltd.**Statement of Financial Position****As at June 30, 2025**

All amounts presented in Bangladesh BDT


| | Notes | 30th June, 2025 | 30th June, 2024 |
|-----------------------------------------------------|-------|----------------------|----------------------|
| Assets | | | |
| Non Current Assets | 4.00 | 1,331,288,575 | 1,389,058,923 |
| Property, Plant & Equipment | 4.01 | 1,329,312,064 | 1,385,909,359 |
| Intangible Assets | 4.02 | 1,976,511 | 2,470,639 |
| Factory Building Work in Progress | 4.03 | - | - |
| Right of use Asset | 4.04 | 0 | 678,925 |
| Current Assets | 5.00 | 1,701,592,796 | 1,568,009,348 |
| Inventories | 5.01 | 660,750,651 | 710,197,932 |
| Advance Deposit & Prepayments | 5.02 | 77,893,002 | 89,209,840 |
| Advance Income Tax | 5.03 | 243,718,402 | 152,397,162 |
| Accounts Receivable | 5.04 | 636,269,539 | 573,042,270 |
| Cash and Cash Equivalents | 5.05 | 82,961,203 | 43,162,144 |
| Total Property and Assets | | 3,032,881,371 | 2,957,068,270 |
| Shareholder's Equity & Liabilities | | | |
| Shareholder's Equity | 6.00 | 2,621,783,580 | 2,604,734,438 |
| Share Capital | 6.01 | 300,560,000 | 300,560,000 |
| Share Premium | 6.02 | 1,708,395,698 | 1,708,395,698 |
| Tax Holiday Reserve | 6.03 | 12,119,070 | 12,119,070 |
| Revaluation Reserve | 6.04 | 351,300,731 | 358,610,853 |
| Retained Earnings | 6.05 | 249,408,082 | 225,048,817 |
| Non-Current Liabilities | 7.00 | 111,290,839 | 101,603,697 |
| Long Term Loan (Non-Current Maturity) | 7.01 | 161,260 | 1,030,628 |
| Deferred Tax Liability | 7.02 | 111,129,579 | 100,573,069 |
| Current Liabilities | 8.00 | 299,806,952 | 250,730,135 |
| Long Term Loan (Current Maturity) | 8.01 | 872,368 | 805,511 |
| Lease Liability (Current Maturity) | 8.02 | 0 | 678,925 |
| Short Term Loan | 8.03 | 24,408,605 | 46,126,483 |
| Unclaimed Dividend Account | 8.04 | 1,261,907 | 1,237,290 |
| Accrued Expenses Payable | 8.05 | 460,000 | 460,000 |
| Creditors and Other Payable | 8.06 | 108,133,174 | 111,013,113 |
| Provision for Income Tax | 8.07 | 164,670,898 | 90,408,813 |
| Total Liabilities and Provisions | | 411,097,791 | 352,333,832 |
| Total Shareholder's Equity & Liabilities | | 3,032,881,371 | 2,957,068,270 |
| Net Assets Value Per Share (NAVPS) | 18 | 87.23 | 86.66 |


Accompanying notes form an integral part of these Financial Statements.


Md. Abu Hana
Chief Financial Officer


Muhammad Tarek Hossain Khan
Company Secretary


Hiroshi Saito
Nominee Director


Md. Javed Iqbal Pathan
Chairman


Md. Abdur Razzaq
Managing Director

Signed in terms of our report of even date annexed.
For and on behalf of
G. Kibria & Co.
Chartered Accountants
Firm's FRC Enlistment No. CAF-001-030

Date: October 27, 2025
DVC: 2510270392AS396923
Place: Dhaka, Bangladesh



A.K. Gulam Kibria, FCA (#392)
Engagement Partner

JMI Syringes & Medical Devices Ltd.
Statement of Profit or Loss and Other Comprehensive Income
For the year ended on June 30, 2025
All amounts presented in Bangladesh BDT


| | Notes | 30th June, 2025 | 30th June, 2024 |
|----------------------------------------------------|-------|-----------------|-----------------|
| Revenue from Net Sales (A) | 9.00 | 1,883,723,920 | 1,793,610,440 |
| Less: Cost of Goods Sold (B) | 10.00 | 1,590,318,980 | 1,503,282,315 |
| Gross Profit / (Loss) (A-B)=C | | 293,404,940 | 290,328,125 |
| Less: Operating Expenses | | | |
| Administrative Expenses | 11.00 | 82,561,388 | 80,648,492 |
| Marketing, Selling and Distribution Expenses | 12.00 | 69,040,441 | 69,821,220 |
| Total Operating Expenses (D) | | 151,601,829 | 150,469,712 |
| Operating Profit / (Loss) (C-D)=E | | 141,803,111 | 139,858,413 |
| Add: Non-Operating Income | | | |
| Other Income | | 1,904,808 | 6,050,495 |
| Foreign Exchange Unrealized Gain/(Loss) | | - | - |
| Foreign Exchange Realized Gain/(Loss) | | - | - |
| Total Non-Operating Income (F) | 13.00 | 1,904,808 | 6,050,495 |
| Less: Non-Operating Expenses | | | |
| Financial Expenses (G) | 14.00 | 8,146,961 | 8,285,101 |
| Net Income before adjustment of WPPF (E+F-G)=H | | 135,560,958 | 137,623,807 |
| Less: Workers Profit Participation Fund (I) | 15.00 | 6,455,284 | 6,553,515 |
| Net Profit before adjustment of Income Tax (H-I)=J | | 129,105,675 | 131,070,292 |
| Less: Income Tax Expenses (K) | 16.00 | 84,184,531 | 92,191,462 |
| Net Profit / (Loss) after Tax (J-K)=L | | 44,921,143 | 38,878,830 |
| Other Comprehensive Income / (Loss) for the year | | - | - |
| Revaluation Surplus | | 2,183,998 | - |
| Total Comprehensive Income for the year | | 47,105,142 | 38,878,830 |
| Earnings Per Share (EPS) | 17.00 | 1.49 | 1.29 |

Accompanying notes form an integral part of these Financial Statements.


Md. Abu Hana
Chief Financial Officer


Muhammad Tarek Hossain Khan
Company Secretary


Hiroshi Saito
Nominee Director


Md. Javed Iqbal Pathan
Chairman


Md. Abdur Razzaq
Managing Director

Signed in terms of our report of even date annexed.
For and on behalf of
G. Kibria & Co.
Chartered Accountants
Firm's FRC Enlistment No. CAF-001-030


A.K. Gulam Kibria, FCA (#392)
Engagement Partner

Date: October 27, 2025
DVC: 2510270392AS396923
Place: Dhaka, Bangladesh



JMI Syringes & Medical Devices Ltd.
Statement of Changes in Equity
For the year ended on June 30, 2025

All amounts presented in Bangladesh BDT

| Particulars | Share Capital | Share Premium | Tax Holiday Reserve | Revaluation Surplus | Retained Earnings | Total |
|--------------------------------------------------|---------------|---------------|---------------------|---------------------|-------------------|---------------|
| Balance as on 01-07-2024 | 300,560,000 | 1,708,395,698 | 12,119,070 | 358,610,853 | 225,048,817 | 2,604,734,438 |
| Addition / Adjustment | - | - | - | 2,183,998 | - | 2,183,998 |
| Dividend (10% Cash for the year-2023-2024) | - | - | - | - | (30,056,000) | (30,056,000) |
| Net Profit after Tax | - | - | - | - | 44,921,143 | 44,921,143 |
| Revaluation Reserve Adjustment (excluding taxes) | - | - | - | (9,494,121) | 9,494,121 | - |
| Balance as on 30-06-2025 | 300,560,000 | 1,708,395,698 | 12,119,070 | 351,300,731 | 249,408,082 | 2,621,783,580 |

For the year ended on June 30, 2024


| Particulars | Share Capital | Share Premium | Tax Holiday Reserve | Revaluation Surplus | Retained Earnings | Total |
|--------------------------------------------------|---------------|---------------|---------------------|---------------------|-------------------|---------------|
| Balance as on 01-07-2023 | 300,560,000 | 1,708,395,698 | 12,119,070 | 366,856,671 | 207,980,169 | 2,595,911,608 |
| Addition / Adjustment | - | - | - | - | - | - |
| Dividend (10% Cash for the year-2022-2023) | - | - | - | - | (30,056,000) | (30,056,000) |
| Net Profit after Tax | - | - | - | - | 38,878,830 | 38,878,830 |
| Revaluation Reserve Adjustment (excluding taxes) | - | - | - | (8,245,818) | 8,245,818 | - |
| Balance as on 30-06-2024 | 300,560,000 | 1,708,395,698 | 12,119,070 | 358,610,853 | 225,048,817 | 2,604,734,438 |

Accompanying notes form an integral part of these Financial Statements.


Md. Abu Hana
 Chief Financial Officer


Muhammad Tarek Hossain Khan
 Company Secretary


Hiroshi Saito
 Nominee Director



Md. Javed Iqbal Pathan
 Chairman
 Date: October 27, 2025
 DVC: 2510270392AS396923
 Place: Dhaka, Bangladesh


Md. Abdur Razzaq
 Managing Director

JMI Syringes & Medical Devices Ltd.
Statement of Cash Flows
For the year ended on June 30, 2025
All amounts presented in Bangladesh BDT


| | 30th June, 2025 | 30th June, 2024 |
|------------------------------------------------------------------------|---------------------|----------------------|
| A. Cash flows from operating activities | | |
| Collection from Sales | 2,190,154,596 | 2,031,940,414 |
| Collection from Others | 1,904,808 | 6,050,495 |
| Payments to Suppliers and Others | (1,993,551,559) | (1,826,039,832) |
| Tax Paid | (91,321,239) | (89,790,985) |
| Net cash generated from operating activities | 107,186,606 | 122,160,093 |
| B. Cash flows from investing activities | | |
| Acquisition of Non-Current Assets | (7,983,316) | (12,696,271) |
| Disposal / adjustment of Assets | 1,149,917 | 1,971,259 |
| Net cash used in investing activities | (6,833,399) | (10,725,012) |
| C. Cash flows from financing activities | | |
| Net Increase / (Decrease) in Long Term Loans | (802,511) | (2,011,779) |
| Net Increase / (Decrease) in Short Term Loans | (21,717,878) | (80,331,228) |
| Net (Increase) / Decrease in Inter Company Advances | - | - |
| Dividend & Dividend Tax Paid | (30,031,383) | (29,734,312) |
| Interest & Bank Charges paid | (8,002,376) | (7,904,793) |
| Net cash (used in) / from financing activities | (60,554,148) | (119,982,113) |
| D. Net increase/(decrease) in cash and cash equivalents (A+B+C) | 39,799,060 | (8,547,032) |
| E. Opening cash and cash equivalents | 43,162,144 | 51,709,175 |
| F. Closing cash and cash equivalents (D+E) | 82,961,203 | 43,162,144 |
| Net Operating Cash Flow Per Share (NOCFPS) | 3.57 | 4.06 |


Accompanying notes form an integral part of these Financial Statements.


Md. Abu Hana
 Chief Financial Officer


Muhammad Tarek Hossain Khan
 Company Secretary


Hiroshi Saito
 Nominee Director


Md. Javed Iqbal Pathan
 Chairman
Date: October 27, 2025
DVC: 2510270392AS396923
Place: Dhaka, Bangladesh


Md. Abdur Razzaq
 Managing Director

JMI Syringes & Medical Devices Ltd.
Notes, Comprising a Summary of Significant Accounting Policies and
Other Explanatory Information
For the year ended 30 June 2025

1. Legal Status & Nature of the Company

- 1.1 JMI Syringes & Medical Devices Ltd.** was incorporated as a Private Limited Company on 5th April 1999 in Bangladesh with an Authorized Capital of Tk. 6,00,00,000/- divided into 600,000 ordinary shares of Tk. 100/= each under the Companies Act., 1994. Subsequently the Company increased its Authorized Capital to Tk. 30,00,00,000/- and reduced the denomination of the shares from Tk. 100/= to Tk. 10/= as per Extra Ordinary General Meeting held on February 04, 2002 and was converted into a Public Limited Company as per Extra Ordinary General Meeting held on August 20, 2002. Again, the Company reverted its denomination of the shares from Tk. 10/= to Tk. 100/= as per Extra Ordinary General Meeting held on May 05, 2003 and went for public issue during that year. Company's share is listed with the Dhaka and Chittagong Stock Exchange Ltd.

The Company has changed its name from **JMI-Bangla Co. Ltd.** to **JMI Syringes & Medical Devices Ltd.** as per an Extra-Ordinary resolution passed on October 01, 2009 and this change has been approved by the Registrar of Joint Stock Companies & Firms on April 15, 2010.

The Company has changed its authorized capital from Tk. 30 Crore to Tk. 100 Crore and reverted its denomination of the share from Tk. 100/= to Tk. 10/= each. So that the Ordinary Shares of the Company has also been changed from 30 Lac to 10 Crore. It was approved by the shareholder an Extra Ordinary General Meeting held on 29th September 2012 and approved by the Registrar of Joint Stock Companies on 14-11-2012.

The Company has raised paid-up capital as per Consent Letter accorded by Bangladesh Securities and Exchange Commission, against issuing 1,11,00,000 Ordinary Share @ BDT 164.10 per share including premium BDT 154.10 per share to NIPRO Corporation, Osaka, Japan. All amount against the above has been received from NIPRO Corporation and presenting in Statement of Financial Position and Paid-up Share was 2,21,00,000 and Paid-up Capital was BDT. 22,10,00,000/= at the end of the year June 30, 2020.

As per regulatory requirement of BSEC to maintaining minimum paid-capital (i.e. Tk. 30 crore) of the Company in the Stock Market, the Shareholders of the Company has been approved 36% Bonus Share (i.e. 36 shares against 100 shares) for all Shareholders for the year ended June 30, 2022 in the 23rd AGM held on December 21, 2022. Total 79,56,000 share were issued @ Tk 10/= each and BDT 7,95,60,000/= added in the Paid-up Capital of the Company and Paid-up Share was 3,00,56,000 and Paid-up Capital was BDT. 30,05,60,000/= at the end of the year June 30, 2023. Return of Allotment (Form-XV) in this regard has been approved the RJSC on 01-02-2023. As such, number of shares has been increased by 79,56,000 shares and total number of shares stands 3,00,56,000 shares. To calculate all the ratios (i.e. EPS, NAVPS, NOCFPS etc.) retrospective effect has been given for all the periods presented as per provision of relevant IAS.

1.2 Address of Registered Office, Corporate Office and Factories:

The Registered Office of the Company is situated at 72/C, Progoti Shoroni, Middle Badda, Dhaka-1212, Bangladesh. The Corporate Office of the Company is situated at "Unique Heights", Level-11, 119, Kazi Nazrul Islam Avenue, Dhaka-1000, Bangladesh. The Share Office of the Company is situated at 29/C & 29/D, Tejgaon Industrial Area, Dhaka-1208 and Factory address of the Company is situated at Noapara, Chaudhagram, Comilla, Bangladesh.

1.3 Nature of Business:

The Company is primarily engaged in business of manufacturing and marketing of Disposable Syringe, Auto Disable Syringe (AD Syringe), Needle (blister pack), Infusion Set, Scalp Vein Set, Urine Drainage Bag, Insulin Syringe, First AID Bandage, Eye Gel Set, Riles Tube, IV Cannula, Feeding Tube, Cooper-T, Blood Lancets, Blood Transfusion Set, 3-Way Stop Cock, Suction Catheter, Alcohol Pad, Nelaton Catheter, Umbilical Cord Clamp, Wound Drain Tube, Spinal Needle, Safety Box etc.

1.4 Commencement of Business:

The Company commenced commercial operation on 26th January 2002. But the operation has stopped for some technical reason for 5 months and commercial operation has restarted from June 18, 2002.

1.5 Number of Employees:

The number of employees at the end of the year was 1173.



2. Basis of Preparation of Financial Statements:

2.1 Statement of Compliance

The financial statements have been prepared in compliance with the requirements of the Companies Act 1994, the Securities & Exchange Rules 1987, the Listing Regulations of Dhaka Stock Exchange (DSE) and Chittagong Stock Exchange (CSE) and other relevant local laws as applicable and in accordance with the applicable International Financial Reporting Standards (IFRSs) including International Accounting Standards (IAS) as issued by International Accounting Standards Board (IASB) and adopted by the Institute of Chartered Accountants of Bangladesh (ICAB).

2.2 Regulatory Compliances

As required by the company, the management complies with the following major legal provisions in addition to the Companies Act 1994 and other applicable laws and regulations:

- i. The Income Tax Ordinance 1984 & Income Tax Act-2023
- ii. The Value Added Tax Act 1991 & The Value Added Tax and Supplementary Duty Act 2012
- iii. The Value Added Tax Rules 1991 & The Value Added Tax and Supplementary Duty Rules 2016
- iv. The Customs Act, 1969;
- v. Bangladesh Labour Law, 2006;
- vi. The Securities and Exchange Ordinance, 1969;
- vii. The Securities and Exchange Rules, 1987;
- viii. Securities and Exchange Commission Act, 1993;
- ix. Dhaka Stock Exchange (Listing) Regulations, 2015 &
- x. Chittagong Stock Exchange (Listing) Regulations, 2015.

2.3 Structure, content and presentation of financial statements

According to the International Accounting Standards (IAS)-1 as adopted by ICAB as IAS-1 "Presentation of Financial Statements" the complete set of financial statements includes the following components.

- i. Statement of financial position as at June 30, 2025;
- ii. Statement of profit or loss and other comprehensive income for the financial year June 30, 2025;
- iii. Statement of cash flows for the financial year June 30, 2025;
- iv. Statement of changes in equity for the financial year June 30, 2025;
- v. Accounting policies and other explanatory notes for the financial year June 30, 2025.

2.4 Applicable Accounting Standards & Financial Reporting Standards

The following IASs and IFRSs are applicable for the financial statements for the year under review:

| Sl. No. | Name of the IAS | IAS's no. |
|---------|-----------------------------------------------------------------|-----------|
| 1 | Presentation of Financial Statements | 1 |
| 2 | Inventories | 2 |
| 3 | Statement of Cash Flows | 7 |
| 4 | Accounting policies, Changes in accounting Estimates and Errors | 8 |
| 5 | Events after the Reporting Period | 10 |
| 6 | Income Taxes | 12 |
| 7 | Property, Plant & Equipment | 16 |
| 8 | Employee Benefits | 19 |
| 9 | The Effects of Changes in Foreign Exchange Rates | 21 |
| 10 | Borrowing Costs | 23 |
| 11 | Related Party Disclosures | 24 |
| 12 | Financial Instruments: Presentation | 32 |
| 13 | Earnings Per Share | 33 |
| 14 | Impairment of Assets | 36 |
| 15 | Provision, Contingent Liabilities and Contingent Assets | 37 |
| 16 | Intangible Assets | 38 |

| Sl. No. | Name of the IFRS | IFRS No |
|---------|------------------------------------|---------|
| 1 | Financial Instruments: Disclosures | 7 |
| 2 | Operating Segments | 8 |



| | | |
|---|------------------------|----|
| 3 | Financial Instruments | 9 |
| 4 | Fair Value Measurement | 13 |
| 5 | Revenue | 15 |
| 6 | Leases | 16 |

2.5 Basis of Measurement:

The financial statements have been prepared on Historical Cost Basis except land building being revalued on 31st December 2012, 3rd December 2015, 25th March 2020 & 31st December, 2024 and the cash flow statement being prepared on cash basis.

2.6 Reporting Period:

The financial statements cover one financial year (12 months) from July 01, 2024 to June 30, 2025.

2.7 Authorization for issue:

The financial statements have been authorized for issue by the Board of Directors on 27th October 2025.

2.8 Functional and Presentation Currency:

The financial statements are prepared and presented in Bangladesh Currency (Taka), which is the company's functional currency. All information presented has been rounded off to the nearest Taka except where indicated otherwise.

2.9 Use of Estimates and Judgments:

The preparation of financial statements in conformity with the IFRSs including IASs require management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses, and for contingent assets and liabilities that require disclosure, during and at the date of the financial statements.

Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision of accounting estimates is recognized in the period in which the estimate is revised and in any future periods affected.

In particular, the key areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements include depreciation, inventory valuation, accrued expenses and other payable.

3.0 Significant Accounting Policies:

The accounting principles and policies in respect of material items of financial statements set out below have been applied consistently to all periods presented in these financial statements.

3.1 Revenue Recognition:

In compliance with the requirements of IFRS 15, the Company recognizes revenue when control of the goods or services has been transferred to the customer and the performance obligation has been completed. Revenue is measured at the fair value of the amount of consideration to which the Company expects to be entitled to, including variable consideration, if any, to the extent that it is highly probable that a significant reversal will not occurred.

Net Revenue reflects the Company's sale of goods less returns and discounts. Revenue is recognized at the point of delivery measured at fair value of the consideration received, net of discounts. IFRS 15 requires Company to determine variable factors such as sales returns when calculating the fair value of the consideration to be received. The magnitude and quantity of sales returns as a percentage of sales has been historically very low. As a result, the Company does not make a sales return allowance at the end of the year. The Company does however monitor the activity of sales returns during the year and the behavior of customers to determine if a sales return allowance is required. As of June 30 2025, no sales return allowance was deemed to be required

Revenue from sales is exclusive of VAT.

Wastage sales are showing in other income (notes-13).

3.2 Property, Plant and Equipment:

3.2.1 Recognition and Measurement:

This has been stated at cost or revalued amount less accumulated depreciation in compliance with the requirements of IAS 16: Property, Plant and Equipment. The cost of acquisition of an asset comprises its purchase price and any directly

attributable cost of bringing the assets to its working condition for its intended use inclusive of inward freight, duties and non-refundable taxes.

3.2.2 Maintenance Activities:

The company incurs maintenance costs for all its major items of property, plant and equipment. Repair and maintenance costs are charged as expenses when incurred.

3.2.3 Depreciation:

Depreciation is provided to amortize the cost of the assets after commissioning, over the period of their expected useful lives, in accordance with the provisions of IAS 16: Property, Plant and Equipment. Depreciation is provided at the following rates on reducing balance basis:

| Sl. No. | Name of Assets | % Of Depreciation |
|---------|------------------------------|-------------------|
| 01. | Land and Land Development | 0% |
| 02. | Factory Building | 5% |
| 03. | Machineries | 7% |
| 04. | Furniture and Fixtures | 10% |
| 05. | Factory and Office Equipment | 10% |
| 06. | Office Decoration | 10% |
| 07. | Power Station | 10% |
| 08. | Air Cooler | 10% |
| 09. | Telephone Line Installation | 10% |
| 10. | Deep Tube-well & Pump | 10% |
| 11. | Crockeries and Cutleries | 10% |
| 12. | Vehicles | 10% |

The company's policy is to transfer excess depreciation of revalued assets are transferred from revaluation surplus to retained earnings excluding taxes. The board of director's has also approved this depreciation rate as per useful life of the fixed assets.

3.2.4 The Changes in Accounting Policy:

The management had changed the rate of depreciation for the following assets from the year-2008 to till now:

| <u>Name of Assets</u> | <u>Present Rate</u> | <u>Previous Rate</u> |
|-----------------------|---------------------|----------------------|
| Factory Building | 5% | 10% |
| Machineries | 7% | 10% |

Rate of depreciation for other assets are consistently following.

3.2.5 Retirements and Disposals:

On disposal of fixed assets, the cost and accumulated depreciation are eliminated and gain loss on such disposal is reflected in the income statement, which is determined with reference to the net book value of the assets and net sales proceeds.

3.2.6 Impairment

The carrying amount of the entity's non-financial assets, other than inventories and deferred tax assets (considered as disclosed separately under respective accounting standards), are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the assets' recoverable amounts are estimated. However, no such conditions that might be suggestive of a heightened risk of impairment of assets existed at the reporting date.

An impairment loss is recognized through the statement of comprehensive income whenever the carrying amount of an asset exceeds its recoverable amount.

The recoverable amount of an asset is calculated as the present value of estimated future cash flows that will be generated using that asset, discounted at an appropriate rate.

Impairment indicators comprise:

- reduced earnings compared to expected future outcome;

- Material negative development trends in the sector or the economy in which the Company operates; - damage to the asset or changed use of asset;

3.3 Leases:

The Company applied IFRS 16 Leases for the first time on 1 July 2019. The nature and effect of the changes as a result of adoption of this new accounting standard is described below.

A Lease is defined as 'a contract, or part of a contract, that conveys the right to use an asset (the underlying asset) for a period of time in exchange for consideration. Previously the Company used to charge the consideration paid in its books as rent expenses. IFRS 16 introduced a single, on balance sheet accounting model for leases. As a result, the Company, as a lessee, has recognized right of use assets representing its rights to use underlying assets and lease liabilities representing its obligation to make lease payments. The Company applied IFRS 16 on 1 January 2019 for the existing lease contracts.

The Company has only office rent agreement, which is classified as operating leases, which under IFRS 16 are required to be recognized on the Company's statement of financial position. The nature and timing of expenses related to those leases has changed as IFRS 16 replaced the straight-line operating lease expense (as per IAS-17) with an amortization charge for the right of use assets and interest expense on lease liabilities.

The Company applied the practical expedient to the definition of a lease on transition. This means that it applied IFRS 16 to all contracts entered into before 1 January 2019 and identified as leases in accordance with IAS 17 and IFRIC 4.

The Company applied IFRS 16 initially on 1 July 2019, using the modified retrospective approach. Accordingly, the comparative information presented for fiscal 2019 has not been restated. The 2019 numbers are presented, as previously reported, under IAS 17 and related interpretations. This includes recognizing a lease liability at 1 July 2019, measured at the present value of the remaining lease payments and discounted at the incremental borrowing rate. A right-of-use asset has been recognized at 1 July 2019 measured at an amount equal to the lease liability and adjusted by any prepaid or accrued lease payments relating to that lease contained in the statement of financial position immediately before 1 July 2019. There was no material impact on the retained earnings due to the transition.

The Company's all contractual payments to the lessor contains only fixed amounts of lease payment and no variable lease payments are embedded with the lease payments. The rental agreements do not include any automatic renewals, nor do they include any guaranteed residual values of the underlying assets.

The Company recognizes **right-of-use assets** at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized, initial direct costs incurred, and lease payments made at or before the commencement date less any lease incentives received. At the commencement date of the lease, the Company recognizes **lease liabilities** measured at the present value of lease payments to be made over the lease term. After the commencement date, the amount of lease liabilities is increased to reflect the accretion of interest and reduced for the lease payments made. In addition, the carrying amount of lease liabilities is re-measured if there is a modification, a change in the lease term or a change in the in-substance fixed lease payments.

The Company do not have renewed office rental agreements in force at this moment. It has been expired on June 30, 2025. Therefore, the company has not shown any lease assets and lease liabilities in this financial statements. If the office rental agreement is renewed or re-enforced, it will be accounted for as per the laws.

3.4 Financial Instruments:

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity.

3.4.1 Financial Assets:

The Company recognizes a financial asset in its statement of financial position, when, and only when, the entity becomes a party to the contractual provisions of the instrument. Financial assets are classified, at initial recognition, as subsequently measured at amortized cost, fair value through other comprehensive income (OCI), and fair value through profit or loss. The classification of financial assets at initial recognition depends on the financial asset's contractual cash flow characteristics and the Company's business model for managing them. Financial assets of the company include

cash and cash equivalents, accounts receivable and other receivables. The company derecognizes a financial asset when and only when the contractual rights or probabilities of receiving the cash flows from the asset expire or it transfer the rights to receive the contractual cash flows on the financial asset in a transaction in which substantially all the risk and rewards of ownership of the financial asset are transferred.

3.4.1(a) Accounts Receivable:

Accounts Receivable are created at original invoice amount less any provisions for doubtful debts. Provisions are made where there is evidence of a risk of non-payment, considering aging, previous experience and general economic conditions. When an accounts receivable is determined to be uncollected it is written off, firstly against any provision available and then to the profit and loss account. Subsequent recoveries of amounts previously provided for are credited to the profit and loss account.

3.4.1(b) Cash and Cash Equivalents:

Cash and cash equivalents include cash in hand, in transit and with banks on current, std. FC and deposit accounts which are held and available for use by the company without any restriction. There is insignificant risk of change in value of the same.

3.4.2 Financial Liability:

Financial liabilities are recognized initially on the transaction date at which the company becomes a party to the contractual provisions of the liability. The company derecognizes a financial liability when its contractual obligations are discharged or cancelled or expire. Financial liabilities include payable for expenses, liability for capital expenditure and other current liabilities.

3.5 Impairment:

Financial assets not carried at fair value through profit or loss and receivables are assessed at each reporting date to determine whether there is objective evidence that any particular asset is impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably.

The carrying value of the non-financial assets, other than inventories, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the asset's recoverable amount is estimated. An impairment loss is recognized whenever the carrying amount of the asset or its cash generating unit exceeds its recoverable amount. Impairment losses, if any, are recognized in the statement of profit or loss and other comprehensive income.

3.6 Inventories:

Inventories are carried at the lower of cost and net realizable value as prescribed by IAS 2: Inventories. Cost is determined on weighted average cost basis. The cost of inventories comprises of expenditure incurred in the normal course of business in bringing the inventories to their present location and condition. Net realizable value is based on estimated selling price less any further costs expected to be incurred to make the sale.

3.7 Provisions:

A provision is recognized in the statement of financial position when the company has a legal or constructive obligation as a result of a past event, it is probable that an outflow of economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. Provision is ordinarily measured at the best estimate of the expenditure required to settle the present obligation at the date of statement of financial position. Where the effect of time value of money is material, the amount of provision is measured at the present value of the expenditures expected to be required to settle the obligation.

3.8 Income Tax Expenses:

Income tax expenses comprises of current and deferred tax. Income tax expenses is recognized in the Statement of Profit or Loss and Other Comprehensive Income and accounted for in accordance with the requirements of IAS 12: Income Tax.

Current tax:

Current tax is the expected tax payable on the taxable income for the year, and any adjustment to tax payable in respect of previous years. The company qualifies as a "Publicly Traded Company"; hence the applicable Tax Rate is 22.50% for profit on local sales & 11.25% for profit on export sales.



Deferred tax:

The company has recognized deferred tax using balance sheet method in compliance with the provisions of IAS 12: Income Taxes. The company's policy of recognition of deferred tax assets / liabilities is based on temporary differences (Taxable or deductible) between the carrying amount (Book value) of assets and liabilities for financial reporting purpose and its tax base, and accordingly, deferred tax income / expenses has been considered to determine net profit after tax and earnings per shares (EPS).

A deferred tax asset is recognized to the extent that it is probable that future taxable profit will be available, against which temporary differences can be utilized. Deferred tax assets are reviewed at each reporting date and reduced to the extent that it is no longer probable that the related tax benefit will be realized.

3.9 Interest Income:

Interest income is recognized on accrual basis.

3.10 Borrowing Cost:

Borrowing costs are recognized as expenses in the period in which they are incurred unless capitalization of such is allowed under IAS 23: Borrowing Costs.

3.11 Employee Benefits:

The company maintains a defined contribution plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective deeds. The Company does not have any defined benefit plans and therefore does not record any provisions or expenses in this regard.

The company has accounted for and disclosed employee benefits in compliance with the provisions of IAS 19: Employee Benefits. The cost of employee benefits is charged off as revenue expenditure in the period to which the contributions relate. The company's employee benefits include the following:

(a) Short-term employee benefits:

Short-term employee benefits include salaries, bonuses, overtime, holiday allowance, TA/DA, leave encashment, meals allowance, transportation, accommodation, etc. Obligations for such benefits are measured on an undiscounted basis and are expensed as the related service is provided.

(b) Contribution to Workers' Profit Participation and Welfare Funds:

This represents 5% of net profit before tax contributed by the company as per Provisions of the Bangladesh Labor (amendment) Act 2014 and is payable to workers as defined in the said law.

(c) Insurance Scheme:

Employees of the company are covered under insurance schemes.

(d) Defined Contribution Plan (Provident Fund):

The company has a registered provident fund scheme (Defined Contribution Plan) for employees of the company eligible to be members of the fund in accordance with the rules of the provident fund constituted under an irrevocable trust. All permanent employees contribute 10% of their basic salary to the provident fund and the company also makes equal contribution.

The Company recognizes contribution to defined contribution plan as an expense when an employee has rendered services in exchange for such contribution. The legal and constructive obligation is limited to the amount it agrees to contribute to the fund.

3.12 Proposed Dividend:

The amount of proposed dividend has not been accounted for but disclosed in the notes to the accounts in accordance with the requirements of International Accounting Standard (IAS) 1: Presentation of Financial Statements. Also the proposed dividend is not considered as liability in accordance with the requirement of International Accounting Standard (IAS) 10: Events after the Reporting Period, because no obligation exists at the time of approval of accounts and recommendation of dividend by the Board of Directors.

3.13 Earnings per Share (EPS):

This has been calculated in compliance with the requirements of IAS 33: Earnings per Share by dividing the basic earnings by the weighted average number of ordinary shares outstanding during the year.



Basic EPS:

The company presents basic earnings per share (EPS) data for its ordinary shares. Basic EPS is calculated by dividing the profit or loss attributable to ordinary shareholders of the company by the weighted average number of ordinary shares outstanding during the period.

Diluted EPS:

Diluted EPS is only being calculated where the company has commitment to issue ordinary share at future date at reporting date. No such commitment is hold by the company at reporting date.

3.14 Foreign Currency Transaction:

Foreign currency transactions are recorded at the applicable rates of exchange ruling at the transaction date. The monetary assets and liabilities, if any, denominated in foreign currencies at the financial position date are translated at the applicable rates of exchanges ruling at that date. Exchange differences are charged off as revenue expenditure in compliance with the provisions of IAS 21: The Effects of Changes in Foreign Currency Rates.

3.15 Statement of Cash Flows:

The Statement of Cash Flow has been prepared in accordance with the requirements of IAS 7: Statement of Cash Flows. The cash generated from operating activities has been reported using the Direct Method as prescribed by the Securities and Exchange Rules, 1987 and as the benchmark treatment of IAS 7, whereby major classes of gross cash receipts and gross cash payments from operating activities are disclosed. In addition, the management disclosed indirect method under IAS-7 statement of cash flows from audit activities as per circular no. Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/ 2006-158/208/Admin/81, dated: 20 June 2018: Reconciliation of Net operating cash flow under Indirect Method.

3.16 Events after Reporting Period:

Even after the reporting period that provide additional information about the company's position at the date of Statement of Financial Position or those that indicate that the going concern assumption is not appropriate are reflected in the financial statements. Events after reporting period that are not adjusting events are disclosed in the notes when material.

3.17 Comparative Information:

Comparative information has been disclosed in respect of the year 2024-2025 & 2023-2024 for all numerical information in the financial statements and the narrative and descriptive information where it is relevant for understanding of the current period financial statements.

Figures for the year 2023-2024 have been re-arranged wherever considered necessary to ensure better comparability with the current period.

In the year of June 30, 2023 the number of shares has been increased by 79,56,000 shares through issuing bonus shares and total number of shares stands 3,00,56,000 shares. To calculate all the ratios (i.e. EPS, NAVPS, NOCFPS etc.) retrospective effect has been given for all the periods presented as per provision of relevant IAS.



JMI Syringes & Medical Devices Ltd.

72/C, Progoti Shoroni, Middle Badda, Dhaka-1212

Notes to the Accounts

For the year ended of June 30, 2025

| | Amount BDT June-2025 | Amount BDT June-2024 |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-------------------------|
| 4.00 Non-Current Assets | 1,331,288,575 | 1,389,058,923 |
| This is made up as follows: | | |
| 4.01 Property, Plant & Equipment | 1,329,312,064 | 1,385,909,359 |
| 4.02 Intangible Assets | 1,976,511 | 2,470,639 |
| 4.03 Factory Building Work-in-Progress | 0 | - |
| 4.04 Right of Use Asset | 0 | 678,925 |
| | 1,331,288,575 | 1,389,058,923 |
| 4.01 Property, Plant & Equipment: | | |
| The details of property, plant & equipment are shown in Annexure-1 | | |
| This is made up as follows: | | |
| Opening Balance (with Revalued Amount) | 2,294,206,588 | 2,291,226,652 |
| Addition during the period | 10,801,379 | 12,696,270 |
| Sales / Transfer | (2,196,874) | (9,716,334) |
| Total Cost | 2,302,811,093 | 2,294,206,588 |
| Less: Accumulated Depreciation (Note 4.01.1) | 973,499,029 | 908,297,229 |
| Carrying Value | 1,329,312,064 | 1,385,909,359 |
| 4.01.1 Accumulated Depreciation | | |
| This is made up as follows: | | |
| Opening Balance | 908,297,229 | 845,290,058 |
| Add: Depreciation during the period (Notes 4.01.2) | 66,248,757 | 70,752,247 |
| Less: Adjustment (Sales / Transfer) | (1,046,957) | (7,745,076) |
| Closing Balance of Accumulated Depreciation | 973,499,029 | 908,297,229 |
| 4.01.2 Allocation of depreciation charge for the period has been made in the accounts as follows: | | |
| Factory Overhead | 64,364,974 | 67,800,395 |
| Administrative Expenses | 1,883,783 | 2,951,852 |
| | 66,248,757 | 70,752,247 |
| 4.02 Intangible Assets | 1,976,511 | 2,470,639 |
| This is made up as follows: | | |
| Opening Balance (Software Development) | 2,470,639 | 2,405,229 |
| Add: Addition during the period | - | 65,410 |
| | 2,470,639 | 2,470,639 |
| Less: Amortization | 494,128 | - |
| | 1,976,511 | 2,470,639 |
| 4.03 Factory Building & Staff Quarter Building Work In Progress : | | |
| This is made up as follows: | | |
| Opening Balance (At Cost) | - | - |
| Addition during the period | - | - |
| Less: Transfer to Assets Schedule for charging depreciation | - | - |
| Net Closing Balance | - | - |
| 4.04 Right of use Asset : | 0 | 678,925 |
| This is made up as follows: | | |
| Opening Balance | 678,925 | 2,536,611 |
| Addition / adjustment during the period | 0 | 0 |
| Less: Amortization during the year | (678,925) | (1,857,687) |
| Closing Balance (WDV) | 0 | 678,925 |
| <div style="border: 1px solid black; padding: 5px;"> <p>4.04 (i) The Company do not have renewed office rental agreements in force at this moment. It has been expired on June 30, 2025. Therefore, the company has not shown any lease assets and lease liabilities in this financial statements. If the office rental agreement is renewed or re-enforced, it will be accounted for as per the laws.</p> </div> | | |
| 5.00 Current Assets: | | |
| This is made up as follows: | | |
| 5.01 Inventories | 660,750,651 | 710,197,932 |
| 5.02 Advance, Deposits & Prepayments | 77,893,002 | 89,209,840 |
| 5.03 Advance Income Tax | 243,718,402 | 152,397,162 |
| 5.04 Accounts Receivable | 636,269,539 | 573,042,270 |
| 5.05 Cash and Cash Equivalents | 82,961,203 | 43,162,144 |
| | 1,701,592,796 | 1,568,009,348 |



| | Amount BDT June-2025 | Amount BDT June-2024 |
|-----------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| 5.01 Inventories : | 660,750,651 | 710,197,932 |
| This is made up as follows: | | |
| A) Raw, Chemical and Packing Materials | | |
| Raw and Chemical materials | 131,170,549 | 177,397,425 |
| Goods In transit | 13,149,119 | - |
| Packing Materials | 70,961,017 | 96,759,138 |
| | 215,280,685 | 274,156,563 |
| B) Work-In-Process | 128,906,993 | 105,808,734 |
| C) Finished Goods | 281,084,023 | 299,948,988 |
| D) Generator Fuel, Stationery, Spare Parts & Others | 35,478,950 | 30,283,647 |
| | 660,750,651 | 710,197,932 |
| 5.01 (i) | As net realisable value of stock of Raw Materials, WIP & Finished Goods are higher than the acquisition cost or manufacturing cost, as such all these items of stocks were valued at cost. | |
| 5.01 (ii) | Last 21st August 2024 at 11.30 PM, our factory and surrounding area was suddenly inundated by severe flood. As a result, the raw materials, packaging materials, finished goods and other items stored inside the factory were destroyed and the total estimated value of the affected inventory is BDT 12.26 crore. This incident was duly reported the BSEC. As our factory building, machinery, equipment, inventory and other assets are industrially insured (for covered all types of industrial risk) we have claimed for recovery. The matter is currently under investigation by the insurance company till the finalization of the report. In accordance with IAS 2: Inventories and IAS 37: Provisions, Contingent Liabilities and Contingent Assets, no receivable for insurance recovery has been recognized at this stage due to the uncertainty regarding the outcome and the amount to be recovered. The full carrying amount of the damaged inventory continues to be presented under Inventory as at the reporting date. | |
| 5.02 Advance, Deposits and Prepayments : | 77,893,002 | 89,209,840 |
| This is made up as follows: | | |
| (i) Security deposit to CPB Samity-2 | 3,006,227 | 3,006,227 |
| (ii) Advance to Employee | (4,837,936) | (4,169,514) |
| (iii) Security Deposit for Office Rent & Depot Rent | 3,053,581 | 3,807,606 |
| (iv) Security deposit to CDBL | 200,000 | 200,000 |
| (v) LC Margin & Others | 6,014,520 | 10,729,611 |
| (vi) Advance to Supplier | 3,228,400 | 5,673,545 |
| (vii) Bank Guarantee & Earnest Money Security | 67,228,210 | 69,962,364 |
| | 77,893,002 | 89,209,840 |
| Maturity analysis for above amount as under: | | |
| Adjustment within 1 year | 71,633,194 | 82,196,007 |
| Adjustment within after 1 year | 6,259,808 | 7,013,833 |
| | 77,893,002 | 89,209,840 |
| 5.02 (i) | BDT 20,47,676/- for the year June-2025 & BDT 1,66,845/- for the year June-2024 of Pubali Bank PLC, SD A/C: 106-131 has been transferred from advance deposits & prepayment accounts (note # 5.02) to Cash & Cash Equivalents (note # 5.05). | |
| 5.03 Advance Income Tax: | 243,718,402 | 152,397,162 |
| This is made up as follows: | | |
| Opening Balance | 152,397,162 | 62,606,177 |
| Addition during the period | | |
| AIT deducted against Sales | 72,884,918 | 88,243,703 |
| AIT deposit against Vehicle | 681,000 | 729,500 |
| AIT deposit against Bank Interest | 267,586 | 1,375,079 |
| AIT deducted against Import of Raw Materials | 17,487,736 | 16,204,681 |
| | 91,321,239 | 106,552,962 |
| Balance after addition | 243,718,402 | 169,159,140 |
| Less: Adjustment | | |
| Less: Tax Refunded up to June-2022 | - | 16,761,978 |
| Closing Balance | 243,718,402 | 152,397,162 |
| 5.03 (i) | At the end of the year-June-2025 advance Income tax and provision of Income taxes upto June 2023 has been adjusted according to the relevant rules considering IAS-12, Income Tax Act-2023 and Income Tax assessment history of the company. | |
| 5.04 Accounts Receivable : | 636,269,539 | 573,042,270 |
| This is made up as follows: | | |
| Opening Balance | 573,042,270 | 466,457,576 |
| Add: Sales with VAT during the period | 2,253,381,865 | 2,138,525,108 |
| Balance after addition | 2,826,424,135 | 2,604,982,684 |
| Less: Realisation / adjustment during the period | 2,190,154,596 | 2,031,940,414 |
| Closing Balance | 636,269,539 | 573,042,270 |
| Add: Unrealized Gain for balance of export sales | - | - |
| Net Closing Balance | 636,269,539 | 573,042,270 |
| Add: Other Receivable | - | - |
| Net Closing Balance | 636,269,539 | 573,042,270 |
| 5.04 (i) | In the month of June 2025, some goods were sold through tender in the Government Office which was realized later. Due to which the accounts receivable has increased slightly compared to the previous year. | |

| | Amount BDT June-2025 | Amount BDT June-2024 |
|------------------------------------|-------------------------|-------------------------|
| 5.04 (ii) Receivable Aging: | | |
| Receivable amount within 30 Days | 161,777,758 | 195,647,146 |
| Receivable amount within 60 Days | 165,472,768 | 145,599,158 |
| Receivable amount within 90 Days | 100,244,664 | 44,740,638 |
| Receivable amount over 90 Days | 208,774,348 | 187,055,327 |
| Total Receivable Amount | 636,269,539 | 573,042,270 |

5.04(iii) **Disclosure for related party transaction as Sundry Debtors:**

| Name | Total Transaction during the year | June 30, 2025 | June 30, 2024 |
|----------------------------------|-----------------------------------|--------------------|--------------------|
| JMI Hospital Requisite Mfg. Ltd. | 24,006,437.87 | - | 34,071,254 |
| JMI Group | - | 95,686 | 95,686 |
| Nipro JMI Medical Ltd. | 513,317,384.32 | 170,772,769 | 125,734,274 |
| Nipro JMI Pharma Ltd. | 14,659,450.37 | 7,382,780 | 2,377,707 |
| Nipro JMI Company Ltd. | - | - | - |
| Nipro Medical Pakistan | 64,050.00 | 64,050 | - |
| Total | 552,047,322.56 | 178,315,285 | 162,278,921 |

5.04(iv) This related party transactions have been done with complying the requirements of the BSEC Notification No. BSEC/CMRRCD/2009-193/10/Admin/118 dated March 22, 2021.

5.05 **Cash & Cash Equivalents:**

82,961,203 43,162,144

This is made up as follows:

Cash at Bank

| | | |
|---------------------------------------------------------|-------------------|-------------------|
| Janata Bank, Corporate Branch, CD A/c-1010216 | 12,944,880 | 322,621 |
| Jamuna Bank, F.Ex. Branch-CD A/c-210005144 | 104,283 | 104,283 |
| Janata Bank, Corporate Branch, STD A/c- 004001122 | - | 43 |
| Janata Bank, Corporate Branch, STD A/c- 004001592 | 2,787,339 | 15,714 |
| Janata Bank, Corporate Branch, FC A/c-402000452 | 132,856 | 132,856 |
| Janata Bank, Chaudhagram Branch, CD A/c- 001006817 | 922,052 | 101,432 |
| Janata Bank, Corporate Branch, STD A/c- 004001119 | - | - |
| AB Bank, IPO A/c-221252430 | 37,699 | 31,218 |
| Agrani Bank PLC, CD A/c-0200018274996 | 12,126 | 12,954 |
| Bank Asia PLC, SND A/c: 08536000137 | 8,842 | - |
| Pubali Bank PLC, STD A/c-2001221 | 35,947,321 | 21,452,470 |
| Pubali Bank PLC, STD A/c-0106102001368 (Dividend) | 1,247,951 | 1,211,064 |
| Pubali Bank PLC, STD A/c-3850102000116 | 30,613 | 535,682 |
| Pubali Bank PLC, SD A/c-106-131 | 2,047,676 | 166,845 |
| Standard Bank PLC, Motijheel Branch, CD A/c-00233012214 | 2,170,509 | 131,954 |
| Dutch Bangla Bank PLC, CD A/c-10411024464 | 65,478 | 66,168 |
| Dutch Bangla Bank PLC, STD A/c-1011205276 | 14,054,166 | 13,837,985 |
| | 72,513,789 | 38,123,289 |

Cash In Hand

| | | |
|------------------------|-------------------|-------------------|
| Head Office | 4,849,642 | 1,999,728 |
| Factory Office | 5,597,772 | 3,039,127 |
| | 10,447,414 | 5,038,855 |
| Closing Balance | 82,961,203 | 43,162,144 |

5.05 (i) BDT 20,47,676/- for the year June-2025 & BDT 1,66,845/- for the year June-2024 of Pubali Bank PLC, SD A/C: 106-131 has been transferred from advance deposits & prepayment accounts (note # 5.02) to Cash & Cash Equivalents (note # 5.05).

6.00 **Shareholders' Equity**

2,621,783,580 2,604,734,438

This is made up as follows:

| | | |
|--------------------------|----------------------|----------------------|
| 6.01 Share Capital | 300,560,000 | 300,560,000 |
| 6.02 Share Premium | 1,708,395,698 | 1,708,395,698 |
| 6.03 Tax Holiday Reserve | 12,119,070 | 12,119,070 |
| 6.04 Revaluation Reserve | 351,300,731 | 358,610,853 |
| 6.05 Retained Earnings | 249,408,082 | 225,048,817 |
| | 2,621,783,580 | 2,604,734,438 |

6.01 **Share Capital**

300,560,000 300,560,000

This is made up as follows:

| | | |
|--------------------------------------------------------------------------|----------------------|----------------------|
| 6.01 (i) Authorized Share Capital | | |
| 10,00,00,000 Ordinary Shares of Tk.10/- each | 1,000,000,000 | 1,000,000,000 |
| 6.01 (ii) Ordinary Share Capital: | | |
| Issued, Subscribed & Paid up Capital : | | |
| 3,00,56,000 Ordinary Shares of Tk.10/- each at par fully paid up in cash | 300,560,000 | 300,560,000 |
| This is made up as follows: | | |
| Opening Balance | 300,560,000 | 300,560,000 |
| Addition during the period | - | - |
| Closing Balance | 300,560,000 | 300,560,000 |

6.01 (iii) As per regulatory requirement of BSEC to maintaining minimum paid-capital (i.e. Tk. 30 crore) of the Company in the Stock Market, the Shareholders of the Company has been approved 36% Bonus Share (i.e. 36 shares against 100 shares) for all Shareholders for the year ended June 30, 2022 in the 23rd AGM held on December 21, 2022. Total 79,56,000 share were issued @ Tk 10/= each to the respective shareholders BO Accounts through CDBL System which name appear in the Members / Depository Registrar on the record date on November 14, 2022. Return of Allotment (Form-XV) in this regard has been submitted to the RJSC on 11-01-2023 and approved on 01-03-2023.



Amount BDT
June-2025

Amount BDT
June-2024

6.01 (iv) The classification of Shareholders by holding as on June 30, 2025 as follows:

| Ranges of Holdings in number of shares | Number of Shareholders | | % Of Shareholders | | Number Of Shares | | % Of Share Capital | |
|----------------------------------------|------------------------|-------|-------------------|-------|------------------|------------|--------------------|--------|
| | 2025 | 2024 | 2025 | 2024 | 2025 | 2024 | 2,025 | 2,024 |
| 1 to 500 | 3,470 | 4,378 | 71.43 | 72.91 | 459,612 | 580,151 | 1.53 | 1.93 |
| 501 to 5,000 | 1,193 | 1,424 | 24.56 | 23.71 | 1,830,523 | 2,135,910 | 6.09 | 7.11 |
| 5001 to 10,000 | 95 | 97 | 1.96 | 1.62 | 677,677 | 677,574 | 2.25 | 2.25 |
| 10,001 to 20,000 | 57 | 63 | 1.17 | 1.05 | 761,895 | 853,373 | 2.53 | 2.84 |
| 20,001 to 30,000 | 12 | 13 | 0.25 | 0.22 | 277,350 | 309,034 | 0.92 | 1.03 |
| 30,001 to 40,000 | 6 | 8 | 0.12 | 0.13 | 216,765 | 282,238 | 0.72 | 0.94 |
| 40,001 to 50,000 | 5 | 5 | 0.10 | 0.08 | 211,930 | 228,272 | 0.71 | 0.76 |
| 50,001 to 100,000 | 4 | 4 | 0.08 | 0.07 | 256,215 | 254,936 | 0.85 | 0.85 |
| 100,001 to 1,000,000 | 12 | 9 | 0.25 | 0.15 | 3,721,619 | 3,092,098 | 12.38 | 10.29 |
| Over 10,00,000 | 4 | 4 | 0.08 | 0.07 | 21,642,414 | 21,642,414 | 72.01 | 72.01 |
| | 4,858 | 6,005 | 100 | 100 | 30,056,000 | 30,056,000 | 100.00 | 100.00 |

Market Price of Ordinary Shares:

The shares are listed with Dhaka and Chittagong Stock Exchange. On the last working day of the year, each share was quoted at BDT 130.50 in Dhaka Stock Exchange Limited and BDT 134.20 in Chittagong Stock Exchange Limited.

| | | |
|---------------------------------------|---------------|---------------|
| 6.01 (v) Composition of Shareholding: | 30,056,000 | 30,056,000 |
| Sponsors | | |
| Bangladeshi | 7,074,039 | 7,074,039 |
| Foreigners | 16,864,000 | 16,864,000 |
| | 23,938,039 | 23,938,039 |
| Public Shares | | |
| General Public | 4,484,355 | 4,793,932 |
| Institution | 1,633,606 | 1,324,029 |
| | 6,117,961 | 6,117,961 |
| 6.02 Share Premium | 1,708,395,698 | 1,708,395,698 |

6.02 (i) The Company received Share Money Deposit from NIPRO Corporation, Osaka, Japan in the year ended June 30, 2019 worth BDT 164.10 per share for 11,100,000 shares which included share premium of BDT 154.10 per share. The funds were received as per Consent letter accorded by Bangladesh Securities & Exchange Commission. Total proceeds received after netting of relevant charges and expenses was BDT 1,819,395,698. The Company issued 11,100,000 at BDT 10.00 per share against this Deposit during the year ended June 30, 2020 and the remaining balance is presented as Share Premium on the Statement of Financial Position.

| | | |
|-----------------------------------------------------------------------------------------------------------|------------|------------|
| 6.03 Tax Holiday Reserve : | 12,119,070 | 12,119,070 |
| This has been provided for as per provision of the Income Tax Ordinance 1984 which is arrived as follows: | | |
| Opening Balance | 12,119,070 | 12,119,070 |
| Addition during the period | - | - |
| Closing Balance | 12,119,070 | 12,119,070 |

6.03 (i) As per circular of NBR the tax holiday reserve has been made @40% on net profit earned by the Company up to 31-12-2006.

| | | |
|---------------------------|-------------|-------------|
| 6.04 Revaluation Reserve: | 351,300,731 | 358,610,853 |
|---------------------------|-------------|-------------|

6.04 (i) The Company has revalued of their land and factory building by Axis Resources Ltd. and certified by Hoda Vasi Chowdhury & Co., Chartered Accountants as of 30th September, 2012, following "Current cost method". Such revaluation resulted into a revaluation surplus aggregating Tk. 35,04,06,455/-. Again the company has revalued of their Land & Factory Building on the basis of 30th September, 2015 by M/S. Malek Siddiqui Wali, Chartered Accountants and revaluation surplus aggregating Tk. 9,98,01,289/-. Again the company has revalued of their Land & Factory Building on the basis of the June 30, 2019 by M/S. Malek Siddiqui Wali, Chartered Accountants and revaluation surplus aggregating Tk. 101,875,578/= Again the company has revalued of their Land & Factory Building on the basis of the December 31, 2024 by M/S. Malek Siddiqui Wali, Chartered Accountants and revaluation surplus aggregating Tk. 28,18,062.57. Current balance is arrived at as follows:

| | | |
|----------------------------------------------------------------------------|-------------|-------------|
| Opening Balance (WDV) | 358,610,853 | 366,856,671 |
| Add: Addition / adjustment during the period | 2,183,998 | (0) |
| Less: Deferred Tax related to assets revaluation | - | - |
| Less: Depreciation on revalued assets (after adjustment of deferred taxes) | (9,494,121) | (8,245,818) |
| Closing Balance (WDV) | 351,300,731 | 358,610,853 |

| | | |
|-----------------------------------------------------------------|--------------|--------------|
| 6.05 Retained Earnings: | 249,408,082 | 225,048,817 |
| This is made up as follows: | | |
| Opening Balance | 225,048,817 | 207,980,169 |
| Less: Dividend for the year-2023-2024 (10% Cash) | (30,056,000) | (30,056,000) |
| Add: Net Profit /(Loss) after Tax | 44,921,143 | 38,878,830 |
| | 239,913,961 | 216,802,999 |
| Add: Revaluation Reserve Adjustment (After adjustment of taxes) | 9,494,121 | 8,245,818 |
| | 249,408,082 | 225,048,817 |
| Less: Set off with AIT up to Sept-2023 | - | 0 |
| Add: Adjustment | 0 | - |
| | 249,408,082 | 225,048,817 |



| | Amount BDT June-2025 | Amount BDT June-2024 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| 6.05 (i) | <p>As per regulatory requirement of BSEC to maintaining minimum paid-capital (i.e. Tk. 30 crore) of the Company in the Stock Market, the Shareholders of the Company has been approved 36% Bonus Share (i.e. 36 shares against 100 shares) for all Shareholders for the year ended June 30, 2022 in the 23rd AGM held on December 21, 2022. Total 79,56,000 share were issued @ Tk 10/= each and BDT 7,95,60,000/= added in the Paid-up Capital of the Company. Return of Allotment (Form-XV) in this regard has been submitted to the RJSC on 11-01-2023 and approved on 01-03-2023.</p> | |
| 7.00 Non-Current Liabilities | 111,290,839 | 101,603,697 |
| 7.01 Long Term Loan (Non-Current Maturity) | 161,260 | 1,030,628 |
| 7.02 Deferred Tax Liability | 111,129,579 | 100,573,069 |
| | 111,290,839 | 101,603,697 |
| 7.01 Long Term Loan-Payable (Non Current Maturity) | | |
| This represents current portion of long term secured loan from financial Institutions which are repayable within after 12 months from July, 2025 and consists of the following: | | |
| Pubali Bank Ltd, 8B Avenue Corporate Branch, Dhaka | | |
| | 161,260 | 1,030,628 |
| | 161,260 | 1,030,628 |
| 7.02 Deferred Tax Liability | 111,129,579 | 100,573,069 |
| This is made up as follows: | | |
| Opening Balance | | |
| | 100,573,069 | 98,790,420 |
| Adjustment (Error correction to opening balance) | | |
| | - | - |
| Increase in DT due to revaluation | | |
| | 100,573,069 | 98,790,420 |
| Deferred Tax (Gain) / Loss at accounting base during year (P/L) | | |
| | 9,922,447 | 1,782,649 |
| Deferred Tax (Gain) / Loss at accounting base during year (OCI) | | |
| | 634,064 | - |
| Closing balance | | |
| | 111,129,579 | 100,573,069 |
| Calculation: | | |
| a) WDV of Fixed Assets (without land) as per Accounting Base | 1,039,389,475 | 1,024,759,588 |
| WDV of Fixed Assets (without land) as per Tax Base | 569,431,553 | 614,458,318 |
| Taxable temporary difference | 469,957,922 | 410,301,270 |
| Deferred Tax Liability (Le Tax Rate 22.5%) | 105,740,532 | 92,317,786 |
| b) WDV of Fixed Assets (land) as per Accounting Base | 291,899,100 | 363,455,000 |
| WDV of Fixed Assets (land) as per Tax Base | 157,172,931 | 157,072,931 |
| Taxable temporary difference | 134,726,169 | 206,382,069 |
| Deferred Tax Liability (Le Tax Rate 4%) | 5,389,047 | 8,255,283 |
| c) Revaluation Surplus (OCI) | - | - |
| Unrealized Gain at tax base | - | - |
| Temporary difference | - | - |
| Tax charges@22.5% | - | - |
| Total Deferred Tax Liability (a+b+c) | 111,129,579 | 100,573,069 |
| Less: Opening Balance of Deferred Tax Liability | 100,573,069 | 98,790,420 |
| Deferred Tax (Gain)/ Expenses for the period | 10,556,511 | 1,782,649 |
| 8.00 Current Liabilities: | 299,806,952 | 250,730,135 |
| This is made up as follows: | | |
| 8.01 Long Term Loan (Current Maturity) | 872,368 | 805,511 |
| 8.02 Lease Liability (Current & Non-Current Maturity) | 0 | 678,925 |
| 8.03 Short Term Loan | 24,408,605 | 46,126,483 |
| 8.04 Unclaimed Dividend Accounts | 1,261,907 | 1,237,290 |
| 8.05 Accrued Expenses Payable | 460,000 | 460,000 |
| 8.06 Creditors and Other Payable | 108,133,174 | 111,013,113 |
| 8.07 Provision for Income Tax | 164,670,898 | 90,408,813 |
| | 299,806,952 | 250,730,135 |
| 8.01 Long Term Loan (Current Maturity) | 872,368 | 805,511 |
| This represents current portion of long term secured loan from financial institutions which are repayable within next 12 months from July, 2025 and consists of the following: | | |
| Pubali Bank Ltd, 8B Avenue Corporate Branch, Dhaka | | |
| | 872,368 | 805,511 |
| | 872,368 | 805,511 |
| a) Lender: Pubali Bank Ltd, 8B Avenue Branch, Dhaka | | |
| b) Security Mortgage/ Lien of Sponsor Director's Share & personal guarantee of all directors of the Company. | | |
| c) Interest 9% p.a. compounded quarterly | | |



| | Amount BDT June-2025 | Amount BDT June-2024 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| 8.02 Lease Liability (Current & Non Current Maturity) | 0 | 678,925 |
| This is made up as follows: | | |
| Opening Balance | 678,925 | 2,536,611 |
| Accretion/Interest Expense during the period | 144,585 | 380,307 |
| Closing Balance after Addition | 823,510 | 2,916,919 |
| Less: Payment during the period | 823,510 | 2,237,994 |
| Closing Liability | 0 | 678,925 |
| The Company do not have renewed office rental agreements in force at this moment. It has been expired on June 30, 2025. Therefore, the company has not shown any lease assets and lease liabilities in this financial statements. If the office rental agreement is renewed or re-enforced, it will be accounted for as per the laws. | | |
| 8.03 Short Term Loan : | 24,408,605 | 46,126,483 |
| This is made up as follows: | | |
| A. PAD-Pubali Bank | 24,408,605 | 46,126,483 |
| B. PAD Standard Bank | - | - |
| Grand Total (A+B) | 24,408,605 | 46,126,483 |
| 8.03 (i) | The above loan was taken from various Banks against mortgage of sponsor share of director of the Company & personal guarantee of all local director's of the Company. This facility availed for yearly basis and rate of interest was Tk. 12.25% P.A. | |
| 8.04 Unclaimed Dividend Account: | | |
| 8.04 (i) Cash Dividend Payable | 1,261,907 | 1,237,290 |
| This is made up as follows: | | |
| Opening Balance | 1,237,290 | 915,602 |
| Addition for the year-2023-2024 (10% cash) | 30,056,000 | 30,056,000 |
| Adjustment / returned for the year | 3,171,038 | 331,737 |
| Balance after addition | 34,464,328 | 31,303,339 |
| Less: Tax at Source Payable | 3,608,687 | 3,942,689 |
| Less: Transfer to Capital Market Stabilization Fund (CMSF) | 161,298 | - |
| Less: Payments during the period | 29,432,436 | 26,123,360 |
| Closing Balance | 1,261,907 | 1,237,290 |
| 8.04 (ii) Summary of Unclaimed Dividend (Cash): | | |
| For the year 2019-2020 | - | 222,063 |
| For the year 2020-2021 | 621,740 | 621,740 |
| For the year 2021-2022 (Fraction Share only) | 71,799 | 71,799 |
| For the year 2022-2023 | 255,476 | 321,688 |
| For the year 2023-2024 | 312,892 | - |
| Total | 1,261,907 | 1,237,290 |
| Subsequently payment of unpaid dividend to CMS Fund: | | |
| 8.04 (iii) | Unclaimed dividend stands to BDT \$,56,350/= and 45,720 Shares as on reporting date (14-07-2025) (since June-2022 to June-2024) which was dispatched to the shareholders' bank accounts and registered addresses (for cash dividend) for non demate shareholders. We have issued some dividend through bank cheque and this will be clearing soon from Dividend Accounts. Some dividend returned back to Company's accounts due to lack of information on CDBL system and changes of address and other reasons. Stock dividend transferred to the Suspenses BO A/c for Paper Shareholder as per BSEC Directives / Rules. | |
| 8.04 (iv) | Unpaid Dividend from July-2020 to June-2021 BDT 6,21,740/= has been transferred to the Capital Market Stabilization Fund (CMSF) SND A/C No. 0010311521301, Community Bank Bangladesh Ltd., Motijheel Branch, Dhaka by CQ No. AS100-B-3828608 dated: 14-07-2025 of Pubali Bank Limited, Dhaka Stadium Corporate Branch, Dhaka as per BSEC Directive No. BSEC/CMRRCD/2021-386/03; dated 14 January 2021 and the Bangladesh Securities and Exchange Commission (Capital Market Stabilization Fund) Rules, 2021 & BSEC letter No. SEC/SRMIC/165-2020/part-1/166 dated 6 July 2021 and SEC/SRMIC/165-2020/part-1/182 dated 19 July 2021. | |
| 8.04 (v) | Unpaid Dividend from July-2019 to June-2020 BDT 1,61,298/= has been transferred to the Capital Market Stabilization Fund (CMSF) SND A/C No. 0010311521301, Community Bank Bangladesh Ltd., Motijheel Branch, Dhaka by CQ No. AS100-B-3828702 dated: 20-10-2024 of Pubali Bank Limited, Dhaka Stadium Corporate Branch, Dhaka as per BSEC Directive No. BSEC/CMRRCD/2021-386/03; dated 14 January 2021 and the Bangladesh Securities and Exchange Commission (Capital Market Stabilization Fund) Rules, 2021 & BSEC letter No. SEC/SRMIC/165-2020/part-1/166 dated 6 July 2021 and SEC/SRMIC/165-2020/part-1/182 dated 19 July 2021. | |
| 8.04 (vi) | A total of 1876 shares remain unallocated as fractions to some shareholders while distributing the stock dividend for the year 2021-2022. According to BSEC Rules, the said fractional shares has been transferred to the Fraction BO A/c and sold-out in the stock market and BDT 4,77,400/- has been received after deduction of charges. Later the said money was paid to the shareholders through BEFTN as bank on 26th January-2023. | |
| 8.04 (vii) | Unpaid Dividend from July-2017 to June-2019 BDT 2,89,753/= has been transferred to Capital Market Stabilization Fund (CMSF) SND A/C No. 0010311521301, Community Bank Bangladesh Ltd., Gulshan Corporate Branch, Dhaka by CQ No. AS100-C-2745958 dated 16-05-2023, Pubali Bank Limited, B.B. Avenue Corporate Branch, Dhaka as per BSEC Directive No. BSEC/CMRRCD/2021-386/03; dated 14 January 2021 and the Bangladesh Securities and Exchange Commission (Capital Market Stabilization Fund) Rules, 2021 & BSEC letter No. SEC/SRMIC/165-2020/part-1/166 dated 6 July 2021 and SEC/SRMIC/165-2020/part-1/182 dated 19 July 2021. | |



| | Amount BDT June-2025 | Amount BDT June-2024 |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-------------------------|
| 3.04 (viii) Unpaid Dividend from June-2004 to June-2017 BDT 17,92,909/= has been transferred to Capital Market Stabilization Fund (CMSF) SNO A/C No. 0010311521301, Community Bank Bangladesh Ltd., Gulshan Corporate Branch, Dhaka by CQ No. 2745933 dated 29-08-2021, Pubali Bank Limited, B.B. Avenue Corporate Branch, Dhaka as per BSEC Directive No. BSEC/CMRRCD/2021-386/03; dated 14 January 2021 and the Bangladesh Securities and Exchange Commission (Capital Market Stabilization Fund) Rules, 2021 & BSEC letter No. SEC/SRMIC/165-2020/part-1/166 dated 6 July 2021 and SEC/SRMIC/165-2020/part-1/182 dated 19 July 2021. | | |
| 8.04 (ix) Stock / Bonus Dividend Payable (In Share Qty) | | |
| This is made up as follows: | | |
| Opening Balance | 45,720 | 45,720 |
| Addition for the year-2021-2022 (36% Bonus Share) | - | - |
| Balance after addition | 45,720 | 45,720 |
| Less: Paid / Issued / transferred during the period | - | - |
| Closing Balance | 45,720 | 45,720 |
| 8.04 (x) As per regulatory requirement of BSEC to maintaining minimum paid-capital (i.e. Tk. 30 crore) of the Company in the Stock Market, the Shareholders of the Company has been approved 36% Bonus Share (i.e. 36 shares against 100 shares) for all Shareholders for the year ended June 30, 2022 in the 23rd AGM held on December 21, 2022. Total 79,56,000 share were issued @ Tk 10/= each and BDT 7,95,60,000/= added in the Paid-up Capital of the Company. Total 45,720 shares wasn't transferred whose shareholders holding shares in paper mode as on record date November 14, 2022. As per BSEC rules this un-distributed shares were transferred to the Suspense BO Accounts of the Company. If any shareholder whose shares are in paper form wants to take bonus shares, their shares must be demate first. Then they have to apply to the company, the company will verify it and transfer the bonus shares to the BO Accounts of respective shareholders. It is noted here that the un-distributed dividend will be transferred to the CMS fund after 3 years as per BSEC rules. | | |
| 8.05 Accrued Expenses Payable | 460,000 | 460,000 |
| This is made up as follows: | | |
| Interest & Charges Payable for Long Term Loan | - | - |
| Interest & Charges Payable for Short Term Loan A/c | - | - |
| Audit Fees for the year ended 30-06-2025 | 460,000 | 460,000 |
| | 460,000 | 460,000 |
| 8.06 Creditors and Other Payables : | 108,133,174 | 111,013,113 |
| This is made up as follows: | | |
| Goods & Service | 63,089,557 | 57,063,610 |
| Salary & Bonus Payable | 3,449,972 | 2,782,638 |
| Wages & Bonus Payable | 14,710,475 | 10,907,109 |
| Remuneration & Bonus Payable | 926,910 | 916,590 |
| Electricity Bill Payable-Factory | - | - |
| Electricity Bill Payable-H/O | - | - |
| Telephone & Mobile Bill Payable | 32,898 | 31,720 |
| Gas Bill Payable-H/O | - | - |
| WASA Bill Payable-H/O | - | - |
| TA/DA Bill Payable-Mkt | 32,420 | 31,270 |
| Provident Fund | 944,456 | 8,530,323 |
| VAT & Other Expenses | 16,372,583 | 23,213,083 |
| Tax at Source Payable | 1,871,288 | 673,147 |
| VAT at Source Payable | 247,330 | 310,109 |
| Workers Profit Participation Fund | 6,455,284 | 6,553,515 |
| | 108,133,174 | 111,013,113 |
| 8.07 Provision for Income Tax | 164,670,898 | 90,408,813 |
| This is made up as follows: | | |
| Opening Balance | 90,408,813 | - |
| Provision for Current Tax for the year (Note: 16) | 74,262,085 | 90,408,813 |
| Less: Net Off with AIT up to June, 2023 | - | - |
| Closing Balance | 164,670,898 | 90,408,813 |
| 8.07 (i) At the end of the year-June-2025 advance income tax and provision of income taxes upto June 2023 has been adjusted according to the relevant rules considering IAS-12, Income Tax Act-2023 and Income Tax assessment history of the company. | | |
| | July-2024 to June-2025 | July-2023 to June-2024 |
| 9.00 Revenue from Net Sales: | | |
| Total Sales with VAT | 2,253,381,865 | 2,138,525,108 |
| Less: VAT | 369,657,945 | 344,914,668 |
| Net Sales Revenue: | 1,883,723,920 | 1,793,610,440 |
| US 16,775/- has been considered for export sales during the year. | | |
| 10.00 Cost of Goods Sold: | | |
| Work-in-Process (Opening) | 105,808,734 | 60,476,108 |
| Raw Materials Consumed (Note-10.02) | 1,002,822,816 | 1,036,033,286 |
| Packing Materials Consumed (Note-10.03) | 220,173,672 | 118,932,284 |
| Factory Overhead (Note-10.04) | 373,439,509 | 345,491,074 |
| Total Manufacturing Cost | 1,702,244,731 | 1,560,932,751 |
| Work-in-Process (Closing) | (128,906,993) | (105,808,734) |
| Cost of Goods Manufactured | 1,573,337,738 | 1,455,124,017 |
| Finished Goods (Opening) | 299,948,988 | 349,893,935 |
| Finished Goods available | 1,873,286,726 | 1,805,017,952 |



| | Amount BDT June-2025 | Amount BDT June-2024 |
|------------------------------------------------------|-------------------------|-------------------------|
| Cost of Physician Sample transferred to Sample Stock | (1,883,724) | (1,786,649) |
| Finished Goods (Closing) | (281,084,023) | (299,948,988) |
| | <u>1,590,318,980</u> | <u>1,503,282,315</u> |

10.01 During the reported year of COGS are slightly increased in comparison with previous year due to increase of US rate for purchasing RM & PM and also increase of salary of factory workers and expenses.

| | | |
|------------------------------|----------------------|----------------------|
| 10.02 Raw Materials Consumed | | |
| Opening Stock | 177,397,425 | 367,360,098 |
| Purchase for the period | 969,745,059 | 846,070,613 |
| Closing Stock | (144,319,668) | (177,397,425) |
| | <u>1,002,822,816</u> | <u>1,036,033,286</u> |

| | | |
|----------------------------------|--------------------|--------------------|
| 10.03 Packing Materials Consumed | | |
| Opening Stock | 96,759,138 | 34,809,999 |
| Purchase for the month | 194,375,551 | 180,881,423 |
| Closing Stock | (70,961,017) | (96,759,138) |
| | <u>220,173,672</u> | <u>118,932,284</u> |

| | | |
|-----------------------------------------|--------------------|--------------------|
| 10.04 Factory Overhead : | | |
| Travelling & Conveyance | 1,040,422 | 673,018 |
| Fuel, Petrol, Light Diesel Etc. | 8,242,180 | 12,174,271 |
| Depreciation | 64,364,974 | 67,800,395 |
| Factory Staff Uniform | 901,874 | 856,350 |
| Electricity Bill | 45,304,108 | 40,860,363 |
| Factory Expenses | 7,113,176 | 10,222,581 |
| Factory Employee Free Lunch | 18,685,008 | 15,696,015 |
| Freight Charge/ Carriage Inward | 676,020 | 656,068 |
| Worker Residential Expenses | 541,200 | 965,600 |
| Insurance Premium | 2,333,160 | 2,333,160 |
| IT & Computer Accessories | 250,059 | 259,779 |
| Laboratory Consumable Stores | 3,211,380 | 2,572,600 |
| Stationery Expenses | 3,011,917 | 3,067,379 |
| Printing Expenses | 617,625 | 648,100 |
| Papers & Periodicals | 9,960 | 9,960 |
| Spare Parts and Accessories Consumption | 9,409,205 | 9,561,121 |
| Municipal Tax | 419,000 | 114,000 |
| Medical expenses | 483,468 | 662,192 |
| Repairs & Maintenance | 1,049,380 | 1,158,703 |
| Telephone & Mobile Bill | 344,250 | 339,149 |
| Remuneration-Director with Bonus | 4,347,000 | 4,200,000 |
| Provident Fund (Companies Contribution) | 4,043,891 | 3,725,158 |
| Research and Development | 130,000 | 368,739 |
| Overtime Expenses | 31,705,943 | 25,595,317 |
| Daily Labour Charge | 1,625,355 | 1,622,862 |
| Salary & Allowances with Bonus | 163,578,954 | 139,348,194 |
| | <u>373,439,509</u> | <u>345,491,074</u> |

- a) Salary and allowances including bonus and leave encashment.
b) The value of stores, spares and other materials cost which are shown in actual consumed cost.
c) Factory expenses & maintenance cost which is included repairs & maintenance of office, premises, building and other infrastructures.

| | | |
|------------------------------------------------------|------------|------------|
| 11.00 Administrative Expenses: | | |
| Advertisement | 382,115 | 378,260 |
| Audit Fee | 460,000 | 460,000 |
| Vehicles Fuel Expenses | 7,431,943 | 7,158,294 |
| Conveyance | 472,889 | 425,132 |
| Depreciation | 2,377,911 | 2,951,852 |
| Electric Bill-H/O | 813,156 | 813,156 |
| Entertainment | 930,882 | 799,387 |
| Fooding Expenses-H/O | 1,726,263 | 1,587,702 |
| Gas Bill | 18,480 | 18,480 |
| Internet Bill | 890,215 | 814,599 |
| Group Insurance | 909,720 | 909,720 |
| Medical Expenses | 727,395 | 608,698 |
| Office Expenses | 3,322,133 | 3,092,028 |
| Amortization Charges for Lease Finance under IFRS-16 | 678,925 | 1,857,687 |
| Overtime | 457,898 | 469,530 |
| Postage and Courier Charge | 18,399 | 9,720 |
| Printing Expenses | 1,322,794 | 1,214,683 |
| Research and Development | 1,201,000 | 1,211,000 |
| Provident Funds (Companies Contribution) | 900,317 | 856,163 |
| Legal & Professional Fees | 449,000 | 180,000 |
| Registration Renewal Fees | 1,272,730 | 1,026,154 |
| Remuneration-Director (with bonus) | 8,508,900 | 8,221,200 |
| Repair & Maintenance H/O | 638,000 | 650,545 |
| AGM, Secretarial & Regulatory Expenses | 1,813,329 | 1,819,460 |
| Salary and allowances (with bonus) | 39,428,467 | 38,323,215 |
| Stationery Expenses | 491,922 | 449,632 |
| Subscription & Annual Membership Exp | 240,000 | 240,000 |
| Internal Employee Training & Development | 367,145 | 360,000 |



| | Amount BDT June-2025 | Amount BDT June-2024 |
|---------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| Telephone and Mobile Bill | 461,321 | 467,791 |
| Travelling Expenses | 3,780,940 | 3,207,205 |
| Water Bill | 67,200 | 67,200 |
| | 82,561,388 | 80,648,492 |
| 12.00 Marketing, Selling and Distrib DIVA Code | | |
| Goods Delivery Expenses (Own Vehicle) | 16,991,889 | 16,237,060 |
| Product Certification, Enlisted & Inclusion Expenses | 5,903,743 | 6,961,602 |
| Fooding & Office Expenses | 1,894,507 | 1,661,304 |
| Exhibition Expenses | 1,087,263 | 922,019 |
| Export Expenses | 64,200 | 165,170 |
| Electricity Bill for Unique Height Level-7 | 132,000 | 141,024 |
| Gas & Water Bill | 186,000 | 187,200 |
| Loading / Unloading & Labour Charge | 406,200 | 207,527 |
| Salary and allowance (with bonus) | 19,741,399 | 18,601,930 |
| Sample Expenses | 9,191,656 | 8,601,091 |
| Promotional Expenses | 9,159,574 | 8,601,478 |
| Incentive Bonus | 368,742 | 3,838,152 |
| Provident Fund (Companies Contribution) | 549,050 | 487,121 |
| T.A & D.A to Marketing Officials | 1,225,670 | 1,214,165 |
| Telephone & Mobile Expenses | 162,228 | 150,993 |
| Tours and Travel | 1,254,000 | 1,123,383 |
| Internal Employee Training & Development | 122,320 | 120,000 |
| Bad Debt Expenses (Written off) | 600,000 | 600,000 |
| | 69,040,441 | 69,821,220 |
| 13.00 Other Income | | |
| Wastage Sales | 450,000 | 408,525 |
| Bank Interest | 1,454,808 | 269,030 |
| Foreign Exchange Unrealized Gain / Loss-Notes-13.01 | - | - |
| Foreign Exchange Realized Gain / Loss-Notes-13.02 | - | - |
| Cash Incentive from Export Sales | - | 5,372,940 |
| Others | - | - |
| | 1,904,808 | 6,050,495 |
| 13.01 Foreign Exchange Unrealized Gain/Loss - Details | | |
| Details are as under : | | |
| Unrealized Gain for balance of export sales | - | - |
| Unrealized Loss ForEx for LC Liabilities (PAD & DEF L/C) | - | - |
| Total Other Comprehensive Income | - | - |
| 13.02 Foreign Exchange Realized Gain/Loss - Details | | |
| Details are as under : | | |
| Realized Gain for Exchange of Import Items.(PAD&DEF L/C) | - | - |
| Realized Loss for Exchange of Import Items.(PAD&DEF L/C) | - | - |
| Total Other Comprehensive Income | - | - |
| 14.00 Financial Expenses: | | |
| Interest & Charges for Short Term Loan | 171,359 | 1,912,366 |
| Interest & Charges for Long Term Loan | 117,301 | 227,898 |
| Interest & Charges for Lease | 144,585 | 380,307 |
| Finance under IFRS-16 | - | - |
| Bank Charges and Commission | 621,287 | 452,693 |
| Realized Loss for Forex Transaction for import of materials | 7,092,428 | 5,311,836 |
| Total Financial Expenses | 8,146,961 | 8,285,101 |
| 15.00 Contribution to WPPF: | 6,455,284 | 6,553,515 |
| 15.01 | This represents statutory contribution by the company as per Bangladesh Labour (amendment) Act, 2013. The amount is computed @ 5% of net profit before tax (but after charging such contribution). Last year's provision was paid during the period in accordance with the requirement of said act. | |
| 16.00 Income Tax Charged for the year: | | |
| Details are as under : | | |
| Current Tax: | | |
| Tax of U/S 163 (old U/S 82C) | 73,833,503 | 90,348,282 |
| On Other Income | 428,582 | 60,532 |
| Total Current Tax | 74,262,085 | 90,408,813 |
| Deferred Tax Expenses / (Gain) - Note # 7.02 | 9,922,447 | 1,782,649 |
| Total Income Tax Charged for the year | 84,184,531 | 92,191,462 |
| Details calculation of Income Tax Charges shown in Annexure-3 | | |
| 17.00 Earning Per Share (EPS): | | |
| (a) Earnings attributable to the Ordinary | 44,921,143 | 38,878,830 |
| (b) Weighted average number of Ordinary Shares outstanding | 30,056,000 | 30,056,000 |
| Earnings Per Share (EPS): [A/B] | 1.49 | 1.29 |
| 17.01 | As per the regulatory requirement of BSEC to maintain minimum paid-capital (i.e. Tk. 30 crore) of the Company in the Stock Market, the company has increased its paid-up capital in this period through issuing 36% bonus share for the year ended June 30, 2022. As such, number of shares has been increased by 79,56,000 shares and total number of shares stands 3,00,56,000 shares. To calculate all the ratios (i.e. EPS, NAVPS, NOCFPS etc) retrospective effect has been given for all the periods presented as per provision of relevant IAS. | |

| | Amount BDT June-2025 | Amount BDT June-2024 |
|-------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|
| 17.02 | During the reported year Sales, Net profit after Tax and Earning per Share (EPS) are increased in comparison with previous year due to increase of sales price of the products and also trying to reducing expenses. | |

| | | | |
|-------|--------------------------------------------------------|---------------|---------------|
| 18.00 | Net Assets Value Per Share (NAVPS): | | |
| (a) | Total Equity attributable to the Ordinary | 2,621,783,580 | 2,604,734,438 |
| (b) | Weighted average number of Ordinary Shares outstanding | 30,056,000 | 30,056,000 |
| | Net Assets Value Per Share (NAVPS): [A/B] | 87.23 | 86.66 |

| | | |
|-------|---------------------------------------------------------------------------------------------------------------------------|--|
| 18.01 | At the end of the current year, the net asset value per share (NAV) has increased slightly compared to the previous year. | |
|-------|---------------------------------------------------------------------------------------------------------------------------|--|

| | | | | |
|-------|--------------------------------------------------------|-------------|--|-------------|
| 19.00 | Net Operating Cash Flow Per Share (NOCFPS): | | | |
| (a) | Operating Cash flow attributable to Ordinary | 107,186,606 | | 122,160,093 |
| (b) | Weighted average number of Ordinary Shares outstanding | 30,056,000 | | 30,056,000 |
| | Net Assets Value Per Share (NAVPS): [A/B] | 3.57 | | 4.06 |

| | | |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| 19.01 | Note: At the end of this period our closing inventory decreased significantly and collection was increases compared to the sales of our products, so that the Net Operating Cash Flow per Share (NOCFPS) was positive by BDT 3.57 | |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|

| | | |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| 19.02 | Clause No. 5 (2) (e) of Notification No. BSEC/CMRRCD/2006-158/208/Admin/81, Dated: 20 June 2019: Reconciliation of Net operating cash flow under Indirect Method: | |
|-------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|

| | | |
|-------------------------------------------------------------------------|---------------|---------------|
| Net Profit | 44,921,143 | 38,878,830 |
| Less: Unrealized FX gain | - | - |
| Add: Def. Tax Exp | 9,922,447 | 1,782,649 |
| Add: Interest paid (excludes interest related to IFRS 16 lease finance) | 8,002,376 | 7,904,793 |
| Add: Depreciation | 66,742,885 | 70,752,247 |
| Add/(Less): Inventory Balance | 49,447,282 | 126,856,009 |
| Add/(Less): Accounts Receivable | (63,227,269) | (106,417,848) |
| Add/(Less): Advance | 11,316,838 | 40,531,149 |
| Add/(Less): AIT Balance | (91,321,239) | (89,790,985) |
| Add/(Less): Accrued Expenses | - | (28,750) |
| Add/(Less): Accounts Payables including OCI impact | 71,382,145 | 31,691,998 |
| Net Operating Cash Flow | 107,186,607 | 122,160,093 |
| Weighted Average Shares Outstanding | 30,056,000.00 | 30,056,000.00 |
| Net Operating Cash flow per share | 3.57 | 4.06 |

20.00 Related Party Transaction-Disclosures under IAS 24 "Related Party Disclosure"

The Company carried out a number of transactions with related parties / associates undertakings in the normal course of business and on arms length basis. The nature of transaction and their total value are in below:

| Name | Total Transaction for the period | Balance as on 30-06-2025 | Balance as on 30-06-2024 |
|-------------------------------------------------------|----------------------------------|--------------------------|--------------------------|
| A. Supplier / Creditors (Payable) | | | |
| JMI Hospital Requisite Mfg. Ltd. | (579,027,669.93) | (12,993,836) | (27,966,065) |
| JMI CNG Dispensing Ltd. | (5,698,395.00) | (181,170) | (395,090) |
| JMI Industrial Gas Ltd. | (40,912,859.00) | (6,920,740) | (14,701,655) |
| JMI Printing & Packaging Ltd. | (190,723,931.90) | (35,137,773) | (7,271,392) |
| Nipro JMI Marketing Ltd. | (13,270,892.00) | (4,740,044) | (1,599,734) |
| Nipro JMI Pharma Ltd. | (46,013.00) | - | - |
| Advance Travel Planner | (652,040.00) | (55,730) | - |
| Nipro JMI Company Ltd. | (173,078.00) | (82,953) | (307,204) |
| JMI Engineering Ltd. | (17,771.00) | 86,600 | 104,371 |
| Total for Supplier/Creditors | (830,522,649.83) | (60,025,645) | (52,136,769) |
| B. Sundry Debtors (Product Sales) (Receivable) | | | |
| JMI Hospital Requisite Mfg. Ltd. | 24,006,437.87 | - | 34,071,254 |
| JMI Group | - | 95,686 | 95,686 |
| Nipro JMI Medical Ltd. | 513,317,384.32 | 170,772,769 | 125,734,274 |
| Nipro JMI Pharma Ltd. | 14,659,450.37 | 7,382,780 | 2,377,707 |
| Nipro JMI Company Ltd. | - | - | - |
| Nipro Medical Pakistan | 64,050.00 | 64,050 | - |
| Total for Sundry Debtors (Product Sales) | 552,047,322.56 | 178,315,285 | 162,278,921 |
| Grand Total | (278,475,327.27) | 118,289,640 | 110,142,152 |

| | | |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|
| 20.01 | This related party transactions have been done with complying the requirements of the BSEC Notification No. BSEC/CMRRCD/2009-193/10/Admin/118 dated March 22, 2021. | |
|-------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|

21.00 Disclosure of key management personal compensation under the Paragraph 17 IAS of 24: "Related Party Disclosures"

The amount of compensation paid to Key Management personal for the year ended June 30, 2025 as under:

| | | |
|------------------------------|-------------------|-------------------|
| Short Term Employee Benefits | 33,470,648 | 31,876,807 |
| Post Employment Benefits | 1,818,901 | 1,732,287 |
| Other Long Term Benefits | - | - |
| Termination Benefits | - | - |
| Share-Based Payment | - | - |
| Total | 35,289,549 | 33,609,094 |

22.00 Attendance Status of Board Meeting of Directors

During the year from 01-07-2024 to 30-06-2025 there were 5 (Five) Board Meetings and 1 AGM were held. The attendance status of all the meetings is as follows:

| 22.01 Name of Director | Positions Held | Meetings Held (#) | | Attended (#) | |
|-------------------------------|-------------------------------------------------|-------------------|-----------|--------------|-----------|
| | | 2024-2025 | 2023-2024 | 2024-2025 | 2023-2024 |
| Md. Javed Iqbal Pathan | Chairman | 6 | 7 | 6 | 7 |
| Md. Abdur Razzaq | Managing Director | 6 | 7 | 6 | 7 |
| Mr. Hoi Kwan Kim | Director | 6 | 7 | 4 | 5 |
| Mr. Takehito Yogo | Nominee Director of Nipro Corporation | N/A | 7 | N/A | 1 |
| Mr. Seigo Tsuchiya | Nominee Director of Nipro Corporation | 6 | 7 | 1 | 1 |
| Mr. Hisao Nakamori | Nominee Director of Nipro Corporation | N/A | 7 | N/A | 6 |
| Mr. Hiroshi Saito | Nominee Director of Nipro Corporation (Retired) | 6 | 7 | 6 | 7 |
| Mr. Kyoetsu Kobayashi | Nominee Director of Nipro Corporation | 6 | 7 | 1 | 1 |
| Mr. Tsuyoshi Yamazaki | Nominee Director of Nipro Corporation | N/A | 7 | N/A | 1 |
| Mr. Koki Hatakeyama | Nominee Director of Nipro Corporation | N/A | 7 | N/A | 1 |
| ATM Serajus Salekin Chowdhury | Independent Director | 6 | 7 | 6 | 7 |
| Muhammod Mustafizur Rahman | Independent Director | 6 | 7 | 6 | 4 |
| Md. Nazrul Islam | Independent Director | 6 | 7 | 1 | 4 |
| Mr. Mr. Hiromasa Wakatake | Nominee Director of Nipro Corporation | 6 | N/A | 4 | N/A |
| Mr. Hiroki Furukawa | Nominee Director of Nipro Corporation | 6 | N/A | 5 | N/A |
| Mr. Kunio Takamido | Nominee Director of Nipro Corporation | 6 | N/A | 1 | N/A |
| Mr. Yoshiharu Yonemori | Nominee Director of Nipro Corporation | 6 | N/A | 1 | N/A |

22.02 Mr. Md. Abdur Razzaq has completed 5 years in the current term as Managing Director and has resigned as per the law and expressed interest for re-appointment. Mr. ATM Serajus Salekin Chowdhury has completed a total of 6 years in two terms as Independent Director and has resigned in accordance with the law and is not eligible for reappointment, so a new independent director will be appointed in his place as per Corporate Governance Code of BSEC.

It is worth noting that in the previous 246th board meeting, it was recommended to appoint 1 (one) independent director and 3 (three) nominated directors on behalf of Nipro Corporation. All are appointment of Director & Nominee Director will be placing to the up-coming 26th AGM for taking approval from Shareholders of the Company.

For Board Meeting, AGM & EGM, attendance fees were paid only to the Independent Directors of the Company.

23.00 Disclosure as per requirement of Schedule XI, Part II of the Company Act, 1984**A. Disclosure as per requirement of Schedule XI, Part II, Note 5 of Para 3.****A (i). Employee Position as at 30th June, 2025**

| Salary Range (Monthly) | Officer & Staff | | Worker | Total Employee |
|------------------------|-----------------|-----------|-------------|----------------|
| | Head Office | Factory | | |
| Below Tk. 5,000 | 0 | 0 | 0 | 0 |
| Above Tk. 5,000 | 78 | 70 | 1025 | 1173 |
| Total | 78 | 70 | 1025 | 1173 |

B. Disclosure as per requirement of Schedule XI, Part II, Para 4

The aggregate amounts paid to / provided for the Directors of the Company for the period ended 30th June-2025 is disclosed below:

| Name of Directors | Designation | Remuneration | Festival Bonus | AIT Deducted | Net Amount |
|-------------------------|----------------------------------------------------------|-------------------|------------------|------------------|-------------------|
| Md. Abdur Razzaq | Managing Director | 5,714,400 | 522,210 | 590,760 | 5,645,850 |
| Md. Abu Jafar Chowdhury | Director-Procurement | 2,794,500 | 255,375 | 288,900 | 2,760,975 |
| Md. Golam Mostafa | Director - Factory | 4,347,000 | 397,250 | 828,750 | 3,915,500 |
| Mr. Hiroshi Saito | Director-Finance & Nominee Director of Nipro Corporation | 4,252,875 | - | 709,344 | 3,543,531 |
| Total | | 17,108,775 | 1,174,835 | 2,417,754 | 15,865,856 |

Period of payment to Directors is from 1st July 2024 to 30th June 2025.

The above Directors of the company did not take any benefit from the company other than the remuneration and festival bonus.

1. Expenses reimbursed to the managing agent: Nil
2. Commission or other remuneration payable separately to a managing agent or his associate: Nil
3. Commission received or receivable by the managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into such concerns with the company: Nil
4. The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the company with the managing agent or his associate during the financial year: Nil
5. Any other perquisites or benefit in cash or in kind stating: Nil
6. Other allowances and commission including guarantee commission: Nil
7. Pensions: Nil
8. Gratuities: Nil
9. Payments from Provident Fund: Nil
10. Compensation for Loss of office: Nil
11. Consideration in connection with retirement from office: Nil



C. Disclosure as per requirement of Schedule XI, Part II, Para 7

| Particulars | Licence Capacity | Installed Capacity In MT (Per Year) | Actual Production In MT from 1 st July, 2024 to 30 th June, 2025 | Capacity Utilization (%) from 1st July, 2024 to 30th June, 2025 |
|----------------------------|------------------------------|-------------------------------------|----------------------------------------------------------------------------------------|-----------------------------------------------------------------|
| Annual Production Capacity | Not mentioned in the Licence | 4,100 | 2,370 | 57.80 |

D. Disclosure as per requirement of Schedule XI, Part II, Para 8

i. Raw Materials, Spare Parts, Packing Materials

| Items | Opening Balance | Purchase | Closing Balance | Consumption In Taka | Percentage % |
|---------------------------|--------------------|----------------------|--------------------|----------------------|---------------|
| Raw Materials & Chemicals | 177,397,425 | 969,745,059 | 144,319,668 | 1,002,822,816 | 103.41 |
| Packing Material | 96,759,138 | 194,375,551 | 70,961,017 | 220,173,672 | 113.27 |
| Spare Parts | 30,283,647 | 14,604,507 | 35,478,950 | 9,409,205 | 64.43 |
| Total | 304,440,210 | 1,178,725,117 | 250,759,635 | 1,232,405,693 | 104.55 |

The value of Imported material is calculated on CIF Basis

ii. The Company has not incurred any expenditure in foreign currency for the period from 1st July 2024 to 30th June 2025 on account of royalty, know-how, professional fee, consultancy fees and interest.

iii. The Company has not earned any foreign exchanges for royalty, know-how, professional fees and consultancy fees.

iv. The value of export from the period from 1st July 2024 to 30th June 2025.

E. Disclosure as per requirement of Schedule XI, Part II, Para 3

| Requirements under condition No. | Compliance status of Disclosure of Schedule XI, Part II, Para 3 | |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|-------------|
| 3(i)(a) The turnover | 1,883,723,920 | |
| 3(i)(b) Commission paid to selling agents (Incentive) | 368,742 | |
| 3(i)(c) Brokerage and discount of sales, other than the usual trade discount | Nil | |
| 3(i)(d)(i) The value of the raw materials consumed, giving item-wise as possible | 1,002,822,816 | |
| 3(i)(d)(ii) The opening and closing stocks of goods produced | Opening Stock | 710,197,932 |
| | Closing Stock | 660,750,651 |
| 3(i)(e) In the case of trading companies, the purchase made and the opening and closing stocks | N/A | |
| 3(i)(f) In the case of Companies rendering or supplying services, the gross income derived from services rendered or supplied | N/A | |
| 3(i)(g) Opening and closing stocks, purchases, sales and consumption of raw materials with value and quantity breakup for the Company, which falls under one or more categories i.e. manufacturing and/or trading | N/A | |
| 3(i)(h) In the case of other companies, the gross income derived under different heads | N/A | |
| 3(i)(i) Work-in-progress, which have been completed at the commencement and at the end of the accounting period | 128,906,993 | |
| 3(i)(j) Provision for depreciation, renewals or diminution in value of fixed assets | 66,248,757 | |
| 3(i)(k) Interest on the debenture paid or payable to the Managing Director, Managing Agent and the Manager | N/A | |
| 3(i)(l) Charge for income tax and other taxation on profits | 84,184,531 | |
| 3(i)(m) Reserved for repayment of share capital and repayment of loans | Nil | |
| 3(i)(n)(i) Amount set aside or proposed to be set aside, to reserves, but not including provisions made to meet any specific liability, contingency or commitment, known to exist at the date as at which the balance sheet is made up. | Nil | |
| 3(i)(n)(ii) Amount withdrawn from above mentioned reserve | Nil | |
| 3(i)(o)(i) Amount set aside to provisions made for meeting specific liabilities, contingencies of commitments. | Nil | |
| 3(i)(o)(ii) Amount withdrawn from above mentioned provisions, as no longer required. | Nil | |
| 3(i)(p) Expenditure incurred on each of the following items, separately for each item: | i) Consumption of stores and spare parts | 9,409,205 |
| | ii) Power & Fuel | 53,546,288 |
| | iii) Rent | 1,220,125 |
| | iv) Repairs of Building | 638,000 |
| | v) Repairs of Machinery | 1,049,380 |
| | vi) a) Salaries, wages & bonus | 222,748,820 |
| | b) Contribution to PF & other funds | 5,493,258 |
| | c) Workmen and staff welfare expenses to the extent not adjusted from any previous provision or reserve. | 6,455,284 |

24.00 Subsequent Disclosure of Events after the Balance Sheet Date - Under IAS 10

The directors recommended 10% Final Cash Dividend (i.e. Tk. 1.00 per share) for the year ended on 30 June, 2025 for all Shareholders. The Dividend proposal is subject to approval of Shareholders' in the forthcoming 26th Annual General Meeting. Excepting to that, no circumstances have arisen since the date of Statement of Financial Position which would require adjustment to, or disclosure in, the financial statements or notes thereto.

25.00 Details of Lease Agreement

There are no leased assets. Therefore, no lease agreement was required or signed.

26.00 (I) Debt considered good in respect of which the company is fully secured: The debtors occurred in the ordinary course of business are considered good and secured.

(II) Debt considered good for which the company hold no security other than the debtor's personal security: There is no such debt in this respect as on 30 June' 2025.

(III) Debt considered doubtful or bad: The company has been made provision for doubtful debts BDT: 6,00,000/= as on 30 June 2025, remaining AR are in good condition because of the fact that sales/export are being made on regular basis with fixed maturity dates.

- (IV) Debt due by directors or other officers of the company: There is no such debt in this respect as on 30th June, 2025.
(V) Debt due by Common Management: There are no amount due from sister company under common management as on 30 June, 2025.
(VI) The maximum amount due by directors or other officers of the company: There is no such debt in this respect as on 30 June, 2025.

27.00 Approval of Financial Statements:

These financial statements were authorized for issue in accordance with a resolution of the company's Board of Directors on 27th October, 2025.

28.00 Internal Control

The following steps have been taken for implementation of an effective internal control procedure of the Company: Regular review of internal audit reports with view to implement the suggestion of internal auditors in respect of internal control technique to establish an effective management system that includes planning, organizing and supervising culture in the factory as well as at Head Office.

29.00 Contingent Liability

There are contingent liabilities amounting to Tk. 12,06,775/- in favor of CMSD for the year ended June 30, 2025.

30.00 Financial Risk Management

International Financial Reporting Standards (IFRS) 7 - Financial Instruments: Disclosures - requires disclosure of information relating to: both recognized and unrecognized financial instruments, their significance and performance, accounting policies, terms and conditions, net fair values and risk information- the Company's policies for controlling risks and exposures.

The management has overall responsibility for the establishment and oversight of the company's risk management framework. The company's risk management policies are established to identify and analyse the risks faced by the company, to set appropriate risk limits and controls, and to monitor risks and adherence to limits. Risk management policies procedures and systems are reviewed regularly to reflect changes in market conditions and the company's activities. This note presents information about the company's exposure to each of the following risks, the company's objectives, policies and processes for measuring and managing risk, and its management of capital. The company has exposure to the following risks from its use of financial instruments.

A. Credit Risk:

Credit risk is the risk of a financial loss to the company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the company's receivables from customers.

Management has a credit policy in place and the exposure to credit risk is monitored on an ongoing basis. In monitoring credit risk, debtors are grouped according to their risk profile, e. i.e. their legal status, financial condition, ageing profile etc. Accounts receivable are related to sale of surgical device products. The maximum exposure to credit risk is represented by the carrying amount of each financial asset in the statement of financial position.

Exposure of Credit Risk

| | 30-Jun-25 | 30-Jun-24 |
|------------------------------------|--------------------|--------------------|
| Trade Debtors (All type) | 636,269,539 | 573,042,270 |
| Advances, Deposits and Prepayments | 77,893,002 | 89,209,840 |
| Cash and Bank Balances | 82,961,203 | 43,162,144 |
| Total | 797,123,744 | 705,414,253 |

Ageing of Receivables

| | 30-Jun-25 | 30-Jun-24 |
|----------------------------------|--------------------|--------------------|
| Receivable amount within 30 Days | 161,777,758 | 195,647,146 |
| Receivable amount within 60 Days | 165,472,768 | 145,599,158 |
| Receivable amount within 90 Days | 100,244,664 | 44,740,638 |
| Receivable amount over 90 Days | 208,774,348 | 187,055,327 |
| Total | 636,269,539 | 573,042,270 |

Credit Exposure by Credit Rating

| | Credit Rating | 30-Jun-25 | 30-Jun-24 |
|------------------------------------|---------------|--------------------|--------------------|
| Trade Debtors (All type) | NR | 636,269,539 | 573,042,270 |
| Advances, Deposits and Prepayments | NR | 77,893,002 | 89,209,840 |
| Cash in Hand | NR | 10,447,414 | 5,038,855 |
| Janata Bank Ltd. | A1 (AAA) | 16,787,127 | 572,666 |
| Arab Bangladesh Bank Ltd. | AA- | 37,699 | 31,218 |
| Pubali Bank Ltd. | AA+ | 37,225,884 | 23,199,215 |
| Standard Bank Ltd. | AA+ | 2,170,509 | 131,954 |
| Dutch Bangla Bank Ltd. | AAA | 14,119,644 | 13,904,154 |
| Agrani Bank Ltd. | A+ (AAA) | 12,126 | 12,954 |
| Jamuna Bank Ltd. | AA1 | 104,283 | 104,283 |
| Total | | 795,067,226 | 705,247,408 |

B. Liquidity Risk:

Liquidity risk is the risk that the company will not be able to meet its financial obligations as they fall due. The company's approach to managing liquidity (cash and cash equivalents) is to ensure, as far as possible, that it will always have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the company's reputation. Typically, the company ensures that it has sufficient cash and cash equivalent to meet expected operational expenses, including financial obligations through preparation of the cash flow forecast, based of time line of payment of the financial obligations and accordingly arrange for sufficient liquidity / fund to make the expected payments within due dates. Moreover, the company seeks to maintain short term lines of credit with scheduled commercial banks to ensure payment of obligation in the event that there is insufficient cash to make the required payment. The requirement is determined in advance through cash flow projections and credit lines with banks are negotiated accordingly.

The following are the contractual maturities of financial liabilities:

| Category of Liabilities | Carrying Amount | Maturity Period | Contractual Cash Flow | Within 6 Months or Less | Within 12 Months or Less |
|-------------------------|--------------------|-----------------|-----------------------|-------------------------|--------------------------|
| Short Term Loan | 24,408,605 | 12 Months | 24,408,605 | 12,204,303 | 12,204,303 |
| Creditors and Accruals | 108,593,174 | 12 Months | 108,593,174 | 54,296,587 | 54,296,587 |
| Total | 133,001,779 | | 133,001,779 | 66,500,889 | 66,500,889 |

C. Market Risk

Market risk is the risk that any change in market prices, such as foreign exchange rates and interest rates will affect the company's income or the value of its holdings financial instruments.



I. Currency risk:

The company is exposed to currency risk on certain revenues and purchases such as raw materials, packing materials, spare parts and acquisition of machineries & equipment. Majority of the company's foreign currency transactions are denominated in USD.

The company have the foreign currency assets at the year-end for which an exchange gain / (loss) are being accounted for during the year. As such the company have no significant exposure to currency risk.

The following significant exchange rates are applied at the end of the year-end:

| Exchange Rate US Dollar | 30-06-2025-BDT | 30-06-2024-BDT |
|-------------------------|----------------|----------------|
| | 122.50 | 117.00 |

II. Foreign Exchange Rate Sensitivity Analysis for Foreign Currency Expenditures:

There being no current risk exposure, sensitivity analysis has not been presented

III. Interest rate risk:

Interest rate risk is the risk that arises due to changes in interest rates on borrowing. The company's exposure to the risk of changes market interest rate relates primarily to the company's short-term finance and term loan. The company's policy is to keep its short-term running finance at lowest level by effectively keeping the positive bank balances. The company made fixed interest rate borrowing from the financial institution under finance lease.

31.00 General Comments and Observations

A. Comparative amount: Previous period's figure have been regrouped / reclassified wherever considered necessary to confirmed to current period's presentation. Figures have been rounded off to the nearest taka, as the currency represented in this financial statement.

B. Presentation currency: The annexed financial statements are presented in Bangladeshi currency (Taka), which have been rounded off to the nearest Taka.

C. All shares have been fully called and paid up.

D. Auditors are paid only statutory audit fees.

E. No foreign exchange remitted to the relevant shareholders during the period under audit.

F. No amount of money was expended by the company for compensating any members of the Board for special service rendered.

G. There was no bank guarantee issued by the company on behalf of Directors.

32.00 Tax Compliance Status

| Year | Total Advance Income Tax | Provision | Advance Income Tax Balance | NBR Demand | Status |
|-------|--------------------------|-------------|----------------------------|--------------|-------------------|
| 2022 | 163,032,304 | 139,261,594 | 23,770,710 | (23,133,557) | Refund Created |
| 2023 | 110,274,703 | 88,201,213 | 22,073,491 | 2,351,610 | Appeal & Tribunal |
| 2024 | 106,552,962 | 90,408,813 | 106,552,962 | 0 | Submitted U/S 180 |
| 2025 | 91,321,239 | 74,262,085 | 91,321,239 | 0 | Audit Process |
| Total | 471,181,209 | 392,133,705 | 243,718,402 | (20,781,947) | |



JMI Syringes & Medical Devices Ltd.
Schedule of Property Plant & Equipments
As at June 30, 2025

1. Before Revaluation :

| Particulars | Cost | | | Depreciation | | | Total as on 30-06-2025 | Sales/ Adjustment | Total as on 30-06-2025 | WDV as on 30-06-2025 |
|--------------------------------|--------------------------|-----------------------|-------------------------------|------------------------|---------|--------------------------|------------------------|-------------------|------------------------|----------------------|
| | Opening as on 01-07-2024 | Addition for the year | Sales/Adjustment t / Transfer | Total as at 30-06-2025 | Rate(%) | Opening as on 01-07-2024 | | | | |
| Land and Land Development | 157,172,931.00 | - | - | 157,172,931 | 0% | - | - | - | - | 157,172,931 |
| Machinery | 1,037,815,713.20 | 2,036,949.09 | - | 1,039,852,662 | 7% | 35,936,219 | 96,345 | 36,032,564 | 560,473,718 | 479,378,945 |
| Factory Buildings | 361,465,907.97 | 2,199,008.00 | - | 363,664,916 | 5% | 11,779,413 | 35,981 | 11,815,394 | 137,693,051 | 225,971,865 |
| Furniture and Fixtures-Factory | 15,274,830.38 | 449,318.00 | - | 15,724,148 | 10% | 688,083 | 26,009 | 714,092 | 9,108,095 | 6,616,053 |
| Office Equipment H.O | 6,250,982.00 | 56,950.00 | - | 6,307,932 | 10% | 3,745,286 | 250,570 | 251,540 | 3,996,826 | 2,311,106 |
| Factory Equipment | 14,129,751.45 | 265,804.00 | - | 14,395,555 | 10% | 10,936,550 | 319,320 | 11,255,870 | 11,274,793 | 3,120,762 |
| Office Decoration | 60,144,273.05 | 2,717,874.40 | - | 62,862,147 | 10% | 37,018,700 | 2,312,557 | 39,331,257 | 39,482,717 | 23,379,430 |
| Deep Tubewell & Pump | 16,133,914.00 | - | - | 16,133,914 | 10% | 10,816,020 | 531,789 | 11,347,809 | 11,347,809 | 4,786,105 |
| Air Cooler | 2,613,733.00 | 212,413.00 | - | 2,826,146 | 10% | 1,853,194 | 76,054 | 1,929,248 | 1,936,428 | 889,718 |
| Power Station | 5,859,010.00 | - | - | 5,859,010 | 10% | 5,596,007 | 26,300 | 5,622,307 | 5,622,307 | 236,703 |
| Telephone Installation | 9,488,775.00 | 45,000.00 | 9,072.00 | 9,524,703 | 10% | 7,012,859 | 247,592 | 7,260,451 | 7,264,950 | 2,259,753 |
| Crockeries and Cutleries | 791,706.00 | - | - | 791,706 | 10% | 700,643 | 9,106 | 709,749 | 709,749 | 81,957 |
| Vehicles | 850,257.00 | - | - | 850,257 | 10% | 632,766 | 21,749 | 654,515 | 654,515 | 195,742 |
| Sub Total as at June 30, 2025 | 1,742,123,265.05 | 7,983,316.49 | 2,196,874.00 | 1,747,909,708 | 10% | 51,943,679 | 1,458,159 | 53,998,278 | 829,526,050 | 1,198,258,588 |

2. Intangible Assets

| Particulars | Cost | | | Depreciation | | | Total as on 30-06-2025 | Sales/ Adjustment | Total as on 30-06-2025 | WDV as on 30-06-2025 |
|-------------------------------|--------------------------|-----------------------|-------------------------------|------------------------|---------|--------------------------|------------------------|-------------------|------------------------|----------------------|
| | Opening as on 01-07-2024 | Addition for the year | Sales/Adjustment t / Transfer | Total as at 30-06-2025 | Rate(%) | Opening as on 01-07-2024 | | | | |
| Software Development | 2,470,639.00 | - | - | 2,470,639 | 20% | 494,128 | - | 494,128 | 494,128 | 1,976,511 |
| Sub Total as at June 30, 2025 | 2,470,639.00 | - | - | 2,470,639 | 20% | 494,128 | - | 494,128 | 494,128 | 1,976,511 |

3. On Revalued Amount :

| Particulars | Cost | | | Depreciation | | | Total as on 30-06-2025 | Sales/ Adjustment | Total as on 30-06-2025 | WDV as on 30-06-2025 |
|---------------------------------|--------------------------|-----------------------|-------------------------------|------------------------|---------|--------------------------|------------------------|-------------------|------------------------|----------------------|
| | Opening as on 01-07-2024 | Addition for the year | Sales/Adjustment t / Transfer | Total as at 30-06-2025 | Rate(%) | Opening as on 01-07-2024 | | | | |
| Land and Land Development | 206,382,069.00 | (71,655,900.00) | - | 134,726,169 | - | - | - | - | - | 134,726,169 |
| Factory Buildings | 345,701,254.00 | 74,473,962.58 | - | 420,175,217 | 5% | 10,698,938 | 1,551,541 | 12,250,479 | 143,972,979 | 276,202,238 |
| Sub Total as at June 30, 2025 | 552,083,323.00 | 2,818,062.58 | - | 554,901,386 | 5% | 10,698,938 | 1,551,541 | 12,250,479 | 143,972,979 | 410,928,407 |
| Grand Total as at June 30, 2025 | 2,296,677,227.05 | 10,801,379.07 | 2,196,874.00 | 2,305,284,732 | 10% | 64,849,977 | 1,892,908 | 66,742,885 | 973,993,157 | 1,331,288,575 |

| Particulars | July-2024 to June-2025 | July-2023 to June-2024 |
|-------------------------|------------------------|------------------------|
| Factory Overhead | 64,364,974.02 | 67,800,395 |
| Administrative Overhead | 2,377,910.81 | 2,951,852 |
| Total | 66,742,884.83 | 70,752,247 |

